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1. p63 SHORT ISOFORMS IN INVASIVE BREAST CARCINOMAS 
 
1.1 INTRODUCTION 
 
1.1.1 p63 
p63 is a sequence-specific DNA-binding factor, homologue of the tumour suppressor 
and transcription factor p53, located on chromosome 3q27-29. Both family members, p53 
and p63, have several common protein domains: a N-terminal transactivation (TA) 
domain, a central DNA-binding domain (DBD) and an oligomerization domain (OD). p63 
isoforms exhibit high degrees of sequence and structural similarity to p53, while at the 
same time revealing considerable functional divergence. All p63 proteins encode a DNA-
binding domain, which is approximately 60% identical at the amino acid level to the 
DNA-binding domain of p53, and an oligomerization domain with about 37% identity to 
that of p53 (Figs. 1.1A and 1.1B) [1]. 
 
1.1.2 Gene Structure 
While p53 is a simple gene, with unique strong promoter with a single transcript 
codifying for only one protein of 393 aminoacids, p63 contains two promoters and is 
characterized by alternative splicing, leading to six different protein [2-4] (Figures 1.1B 
and 1.1C). 
The human p63 gene is composed of 15 exons and transcription can occur from two 
distinct promoters: the transactivating isoforms (TAp63) are generated by a promoter 
upstream of exon 1, while the alternative promoter located in intron 3 leads to the 
expression of N-terminal truncated isoforms (ΔNp63) [5, 6]. C-terminal mRNA splicing 
generates additional structural and functional p63 transcripts. To date three isoforms have 
1.1 Introduction 
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been identified for p63 (α, β, γ), and two for p53 [7, 8]. The different C-termini of α, β, 
and γ isoforms also contribute to the diversity of p63 proteins [9, 10]. 
Shortest isoforms, p63γ, are the more similar to p53. These variants are characterized 
by a splicing that cut off from exon 11 to exon 14. The β-isoforms lack exon 13, while 
isoforms α are the longest one and comprise all 15 with an α-steric (SAM) C-terminal 
(Figure 1.1). 
 
 
Figure 1.1: Functional domains of p53 and p63 proteins. (A) Functional domains of p53. p53 is composed of 
three primary domains: an N-terminal transactivation domain (TA), a central DNA binding domain, and a C-
terminal oligomerization domain (Oligo). (B) Functional domains of p63 proteins. Percentages represent p53-
identical residues found in p63. In addition, p63 has additional C-terminal domains called the sterile alpha motif 
(SAM) domain and transactivation inhibitory domain (TID). (C) Gene structure of p63. Both promoters and the ΔN 
and α, β, γ splicing events are shown. 
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The TAp63α isoform is the largest proteins in each family. The TAp63γ isoform 
most closely resembles full-length p53. In overexpression studies, TAp63γ has been 
shown to be as potent as p53 in inducing target gene expression and apoptosis. p63α 
isoforms also contain a protein–protein interaction domain known as the sterile alpha 
motif (SAM) [10]. The SAM is a globular domain composed of four a-helices and a small 
310-helix. Although this motif is often found to mediate homodimerization within 
developmentally regulated proteins, in p53 family members the SAM domain is thought 
to be monomeric [11]. An additional post-SAM region known as the transactivational 
inhibitory domain (TID) has been identified in p63α [12]. This region (about 70 amino 
acids) has been proposed to inhibit the transcriptional activity of TAp63α through inter- 
or intra-molecular association with the TA domain [12]. Indeed, TAp63α isoforms have 
decreased potency in transactivation and apoptosis induction compared to other TA 
isoforms, and deletion of this region restores transactivation potency of TAp63α [2, 12]. 
The presence of this domain within ΔNp63α isoform may allow trans-repression of 
associated TA isoforms, thereby explaining the potent inhibitory effect of ΔNp63α 
isoform when bound to DNA as hetero-tetramers composed of both ΔNα and TAγ 
isoforms [12]. 
 
1.1.3 p63 Functions 
TAp63 isoforms induce cell cycle arrest, play an important role in cell differentiation 
and also regulate independent sets of genes that are not transcriptional targets of p53 [1]. 
In contrast ΔNp63 proteins act as dominant-negative inhibitors of the p53 family [2, 13], 
leading to the hypothesis that these isoforms may exhibit proto-oncogenic function. In 
normal epithelium, balance between these proteins maintains correct cell proliferation and 
differentiation. Probably an anomalous regulation of the expression of ΔN and TA 
1.1 Introduction 
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proteins might increase the proliferation rate of epithelia, generating the underground for 
neoplastic transformation; moreover, in transforming cells, the imbalance between TA 
and ΔN might cause the characteristic aggressive phenotype, inhibiting the cell cycle 
control by p53. Numerous studies have demonstrated that ΔNp63 is the predominant 
isoform expressed in squamous cell carcinomas of oral cavity [14], while loss of p63 
expression was associated with progression to metastasis and correlated with poor 
prognosis in urothelial carcinomas [15]. 
 
1.1.4 Tissue-specific roles for p63 in normal development 
p63 is expressed in a highly restricted pattern during embryonic development. Its 
expression is first detectable within the primitive ectoderm, which gives rise to the 
epidermis as well as epithelial appendages including the mammary gland, prostate, teeth 
and sweat glands. p63 is also expressed in the apical ectodermal ridge, a specialized 
cluster of ectodermal cells required for inductive events during limb formation [16, 17]. 
Remarkably, p63 is essential for the development of most tissues in which it is expressed, 
as p63-null mice exhibit profound developmental abnormalities of the skin, limbs, 
mammary, prostate and other epithelial tissues [16, 17]. This ectodermal phenotype is 
recapitulated in humans who inherit a variety of heterozygous mutations in p63 that are 
thought to function as dominant-negative or potentially dominant gain-of-function alleles 
[18]. 
 
1.1.5 p63 in normal tissues 
p63 expression follows a restricted pattern in normal tissues. Intense p63 nuclear 
localization in the basal layer of stratified squamous epithelia, with a gradual diminution 
of nuclear intensity in the more terminally differentiated cell layers, whereas the most 
1. p63 short isoforms 
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apical cells had undetectable p63 levels. p63 decorates basal cells of the prostate and of 
the pseudostratified respiratory epithelium, myoepithelial cells of the bronchial glands, 
basa/ myoepithelial cells of breast [19-21]. The identification of p63 in basal cell layers of 
stratified and transitional epithelia is significant because some of these cells act as 
progenitors of the suprabasal cells, which undergo differentiation and cell death [2]. 
Data from TP63 knockout mice point to a pivotal function for p63 in epithelial 
development and morphogenesis [16, 17]. Hence, they displayed defective epidermal 
differentiation as well as agenesis of mammary glands, lacrimal glands, and the prostate. 
It has been reported that p63 overexpression can mimic p53 activities by binding DNA, 
activating transcription, and inducing apoptosis [2, 4, 22]. Whereas p53 is ubiquitously 
expressed, although in low to undetectable levels by IHC, p63 is tissue and cell type 
restricted [2, 23, 24]. It is now evident that p53 has evolved to protect cells from 
genotoxic insults and unprogrammed proliferation, whereas p63 may have evolved to 
perform tissue-specific functions distinct from those of p53 [25]. 
 
1.1.6 p63 in human cancer 
It has been demonstrated that anti-p63 antibodies decorate the majority of squamous 
cell carcinomas of different organs [19-21, 26], including head and neck [14, 27, 28], 
cervix [20] and lung [20, 29], as well as basal cell carcinomas of the skin [19, 30], 
transitional cell carcinomas [20, 31]; moreover tumours with myoepithelial differentiation 
of the breast [32-34] showed strong nuclear p63 expression. p63 is expressed in a minor 
proportion of ductal carcinomas of breast (4.6–11%) [32]. Reports have varied as to the 
frequency of p63 expression in invasive breast carcinomas, with studies ranging from 0 to 
30% [34-36]. It now seems clear, however, that p63 is expressed in at least a subset of 
breast tumours that are known to exhibit a basal epithelial phenotype [37]. Also, some 
1.1 Introduction 
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serous and endometrioid carcinomas of the ovary and rare adenocarcinomas of the colon 
express this marker [21]. p63 also stain rare primary malignant melanomas (10%) and 
glioblastomas (12%) [21]. 
It should be noted, that p63 knockout mice are defective in the development of all 
organs that express p63. Thus, it appears that, in addition to its role in normal 
development, maintenance of p63 expression is important in the neoplastic transformation 
of squamous and transitional epithelium. Mesenchymal elements, including fibroblasts 
and smooth muscle cells, had undetectable p63 [19]. 
 
1.1.7 p63 shorter isoforms 
Two new isoforms have been described with the same sequence as TAp63 and 
ΔNp63 but lacking exon 4: d4TAp63 and ΔNp73L, respectively (Fig. 1.2). ΔNp73L has 
been found only in squamous cell carcinoma of the oral cavity but not in normal oral 
mucosa and normal salivary gland tissues [14, 28, 38]. 
 
 
Figure 1.2: Shorter p63 isoforms. These proteins are identical to normal isoforms except for the splicing 
of exon 4. 
 
 
Immunohistochemical detection of p63 in breast is of practical value as it helps in the 
differential diagnosis between in situ and invasive carcinomas at light microscopy [39, 
40]. Unfortunately the antibodies anti-p63 presently available recognize only ΔNp63 or 
TAp63 isoforms but not those lacking exon 4. 
X 
1. p63 short isoforms 
15 | S p e c i a l  T y p e s  B r e a s t  C a r c i n o m a s  
 
Furthermore no data are available on the molecular expression patterns of p63 N-
terminal isoforms in normal and neoplastic breast tissues. 
Purpose of the study was to investigate the molecular expression of N-terminal p63 
isoforms in benign and malignant breast tissues. 
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1.2 MATERIAL AND METHODS 
 
1.2.1 Case selection 
Forty randomly selected samples of breast tissue, from 32 patients, were collected. 
Criteria for inclusion in the study were the following: 
1) frozen tissue available for molecular study; 
2)  no treatment with any form of adjuvant therapy.  
Tissues were received fresh. Each specimen was visualized at frozen section level. Tissue 
was frozen for molecular analysis, the rest was fixed in 10% buffered formalin and 
processed as routine for diagnosis. Eighteen cases of invasive breast carcinoma (IBC) and 
2 of Ductal In Situ Carcinoma (DIN/DCIS) led to obtain 20 frozen specimens. There were 
also 12 cases of non neoplastic breast tissues that led to an equal number of specimens. 
Finally from tissue of quadrantectomies not involved by the tumour, 8 specimens of 
benign tissue were taken. Therefore in carcinomas each case corresponded to a specimen. 
In non neoplastic tissue the number of specimens was higher than the number of cases. 
Criteria for histological diagnoses were those of WHO [41]. Grading for invasive 
carcinomas were those of Elston and Ellis [42]. Pleomorphic variety of invasive lobular 
carcinomas (PILC) were defined according to the criteria described by Eusebi et. al [43]. 
Rakha et al’s criteria [44] were employed to establish the luminal or basaloid phenotypes. 
 
1.2 Material and Methods 
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1.2.2 Immunohistochemistry 
Immunohistochemistry was performed on 3µm-thick sections cut from selected 
paraffin blocks. All specimens were stained with monoclonal 4A4 antibody 
(Labvision/NeoMarkers, Fremont CA, USA, 1:200), that recognizes all p63 isoforms. The 
additional antibodies reported in Table 1.1 were employed only in cases of IBC. An 
automatic immunostainer (Ventana-Benchmark, Tucson, Arizona, U.S.A.) was used. 
Semiquantitative evaluation was performed counting the percentage of positive neoplastic 
cells in 10 different fields at 40X magnification. 
 
Antibody Dilution Antigen Retrieval 
Ki67* 1:200 CC1^# 
Oestrogen^ Prediluted CC1^# 
Progesterone^ Prediluted CC1^# 
c-erb-B2§ 1:50 CC1^° 
CK14§ 1:400 CC1^° 
Table 1.1: Antibodies employed in cases of IBC. *Dako, Denmark; ^Ventana-
Benchmark, Tucson, Arizona, U.S.A.; §Labvision/NeoMarkers, Fremont CA, USA. 
#Detected by “Universal alkaline phosphatase red detection system” (Ventana-Benchmark); 
°Detected by “Ultraview universal DAB detection system (Ventana-Benchmark) 
 
1.2.3 RNA extraction and RT-PCR 
Before proceeding with molecular analyses, a frozen section was obtained to assess 
the presence of the lesion in the tissue to be processed. Briefly, 5µm frozen sections were 
cut, collected on glass slide and stained with Haematoxilin and Eosin (H&E). After 
morphological evaluation the remnant of the sample was collected in RNAlater (Qiagen, 
Hilden, Germany) and then snap-frozen in liquid nitrogen and stored at –80°C. 
1. p63 short isoforms 
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For each sample 20-80 μg of frozen tissue was treated according to the RNeasy 
Protect Mini Kit protocol (QIAGEN, Hilden, Germany). RNA concentration was 
measured using the Quant-iT™ RNA kit (Invitrogen, Carlsbad, CA). The samples 
concentration was normalized to obtain a total quantity of RNA of about 500ng of each 
sample. cDNA synthesis was carried out using 9 μl of total RNA previously denatured at 
65°C. Retrotranscription was performed at 37˚C for 1 hour in a total volume of 20 μl in 
the presence of 300 ng of random primers (Invitrogen, Milan), 5U of RNase inhibitor (GE 
Healthcare, Milan), 0.5mM ΔNTPs (SIGMA, Milan), 10 mM DTT, and 200 U of MMLV 
(Invitrogen, Milan), followed by a denaturing step at 65 °C for 15 min to inactivate the 
reverse transcriptase. 
 
1.2.4 PCR and Nested-PCR 
The first PCR was performed using the primers reported in Table 1.2. ΔNp63ex3’ 
and ΔNp63ex7out were used to identify the ΔNp73L, TAp63ex2 and TAp63ex5out for 
TAp63 isoforms. 200μM ΔNTPs (Sigma-Aldrich S.r.l., Italy), 1X buffer green (Roche, 
Manheim, Germany), 0.2μM each primer, 1U FastStart Taq Polymerase (Roche, 
Manheim, Germany) and 2μl of cDNA were put in a total reaction volume of 25 μl. After 
a first denaturation step at 95˚ C for four minutes, the reaction continued for 38 cycles of 
95˚C for 30s, 58˚C for 1 min. and 72˚C for 1 min. The final extension was 72˚C for ten 
minutes. The second PCR was carried out changing the two antisense primers: 
ΔNp63ex6nst for ΔNp63 and TAp63ex5nst for TAp63. The reaction contained the same 
reagents of first PCR with the addition of only 1 μl of the first PCR product. The steps of 
reaction were the same of first PCR but not for number of cycle (33 instead of 38). The 
PCR products were run in a 3% agarose gel. A PCR for β-Actin analysis was performed 
1.2 Material and Methods 
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as a reference control with the same conditions specified for p63 using the primers 
reported in Table 1.2 (ActBfw and ActBrv). 
 
Name and Exon Sequence (5’-3’) 
ΔNp63ex3’ (sense) ACCTggAAAACAATgCCCAgAC 
ΔNp63ex7out (antisense) TTCATCCCTCCAACACAACTgC 
TAp63ex2 (sense) ACCCCAgCTCATTTCTCTTggA 
TAp63ex5out (antisense) ggTggggTCATCACCTTgATCT 
ΔNp63ex6nst (antisense) gCATggCTgTTCCCCTCTACTC 
TAp63ex5nst (antisense) ATggggCATgTCTTTgCAATTT 
ActBfw (sense) TTgCCgACAggATgCAgAAggA 
ActBrv (antisense) AggTggACAgCGAggCCAggAT 
Table 1.2: Primers used for PCR and nested-PCR analysis. 
 
1.2.5 Band purification and sequence analysis 
To be sure that the bands visualized in the agarose gel correspond to isoforms under 
study we cut them off from the gel and sequenced. The bands were cut off and treated 
following the protocol of the MinElute Gel Extraction kit (QIAGEN, Hilden, Germany). 
Preparations of the ΔNA sequencing reactions were performed in agreement with the 
CEQ2000 Dye Terminator Cycle Sequencing with Quick Start Kit (Beckman Coulter, 
Fullerton, CA, USA). After purification with the Agencourt CleanSEQ kit (Agencourt, 
1. p63 short isoforms 
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Beverly MA), the products were loaded on the CEQ2000 (Beckman Coulter, Fullerton, 
CA, USA). 
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1.3 RESULTS 
 
All the patients were female, ranging in age from 37 to 83 years (mean 59.1 years). 
The samples under study included 15 normal breasts, 1 cystic disease with apocrine cyst, 
2 fibroadenomas, 2 specimens containing predominantly epitheliosis (usual duct 
hyperplasia) and 20 carcinomas: 12 Invasive Ductal Carcinomas (IDC) (6 grade II, 6 
grade III), 2 DIN/DCIS, 6 invasive lobular carcinomas (ILC), of which 3 were of the 
pleomorphic variety. All the carcinomas presented a “luminal” phenotype. Specifically all 
cases were positive for oestrogen and progesterone receptors and negative for keratin 14 
(Tabs. 1.3-1.4). 
 
Tissue 
Number of 
specimens 
p63 IHC* 
p63 Isoforms (nested PCR) 
ΔNp63 ΔNp73L TAp63 d4TAp63 
        
Normal 15 + 15/15 0/15 12/15 0/15 
        
Apocrine Cyst 1 + 1/1 0/1 0/1 0/1 
        
Fibroadenoma 2 + 2/2 0/2 2/2 0/2 
        
Epitheliosis 2 + 2/2 0/2 1/2 0/2 
Table 1.3: Immunocytochemical and molecular findings in normal tissues and benign breast tissues. *positivity is 
limited to myoepithelial cells located around ducts and lobules.
  
Case Sex/ Age Diagnosis Grade pT pN 
IHC p63 isoforms (nested PCR) 
ER
% PR% 
Ki67 
% 
HER2/ 
Neu CK14 p63%* ΔNp63 ΔNp73L TAp63 d4TAp63 
                
1 68 PILC III 2 2A 80 70 12 2+ - - + + + + 
2 51 PILC  III 3 1A 70 - 15 - - - + + + - 
3 66 PILC  III 1c 3 90 50 15 - - rare + - + - 
4 75 ILC II 2 0 80 - 15 3+ - - + - + - 
5 73 ILC III 1c 1A 30 - 20 2+ - - + - + + 
6 50 ILC II 1c 0 60 90 5 - - - + - + - 
                
7 72 IDC III 2 0 90 90 40 - - - + - + + 
8 52 IDC III 2 1A 60 50 25 3+ - 10% + + + + 
9 56 IDC II 2 2A 90 - 6 3+ - rare + - + - 
10 67 IDC II 1c 2A 90 90 5 2+ - - + - - - 
11 37 IDC II 1a 0 90 70 30 - - - + - + + 
12 80 IDC II 2 0 90 90 10 - - - + - + - 
13 75 IDC III 2 3A 80 15 20 3+ - 5% + - + + 
14 74 IDC III 1c 0 90 80 30 2+  - rare + - + + 
15 58 IDC II 1b 0 90 50 15 1+ - rare + + + + 
16 53 IDC III 2 3A 90 40 25 3+ - - + - + + 
17 49 IDC III 2 1A 90 60 25 1+ - - + - + + 
18 53 IDC II 1c 0 90 30 5 -  - - + - + + 
                
19 66 DCIS III / / np np np np np np + - - - 
20 58 DCIS II / / np np np np np np + - + - 
                
Table 1.4: Histological, immunohistochemical and molecular findings in carcinomas. ILC: Invasive Lobular Carcinoma; IDC: Invasive Ductal Carcinoma; DCIS: 
Ductal Carcinoma in Situ; PILC: Pleomorphic ILC; T: tumour ; N: lymph nodes ; *percentage evaluate in neoplastic cells (excluding normal myoepithelial cells present); +: 
positive; -: negative; rare: up to 1% of positivity; Er: Oestrogen receptors; Pr: Progesterone receptors; CK: Cytokeratin; na: not available; ned: no evidence of disease; Met:  
distant metastases; Met∞: distant metastases at presentation; np: not performed.
1. p63 short isoforms 
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1.3.1 Immunohistochemical results 
Normal breast and benign lesions (Table 1.3): the p63 and CK14 antibodies stained 
the nuclei and cytoplasm respectively of myoepithelial cells that were present in the ducts 
and acini. No staining was observed in luminal cells (Fig. 1.3). 
Carcinomas (Table 1.4): in four cases p63 antibody stained the nuclei of rare (no 
more than 1%) neoplastic cells scattered through the invasive carcinoma. In two 
additional cases p63 antibody stained 5% (case 13) and 10% (case 8) of the neoplastic 
cells (Fig. 1.4). In this latter case p63 positive neoplastic cells were detected also in the 
related lymph node metastasis. No p63 positive cells were detected in the remaining 14 
carcinomas. Myoepithelial cells of residual normal ducts, when present, in the different 
sections constituted internal positive controls. 
 
 
Figure 1.3: Case 1: Pleomorphic invasive lobular carcinoma. 
Myoepithelial cells only stain for p63 in one entrapped non neoplastic 
small duct. 
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Figure 1.4: Case 8: IDC grade III. p63 stains myoepithelial cells of one 
entrapped non neoplastic small duct as well as 10% of nuclei of 
neoplastic elements. 
 
 
1.3.2 Nested PCR 
Normal breast and benign lesions (Table 1.3): all samples expressed ΔNp63, TAp63 or 
both isoforms at the same time. ΔNp63 was expressed in all samples, while TAp63 was 
expressed in 15 out of 20 (75%) samples. The short variants, ΔNp73L and d4TAp63, 
were never expressed. 
Carcinomas (Table 1.4): all cases of in situ and invasive carcinomas expressed 
ΔNp63, TAp63 or both isoforms at the same time. ΔNp63 was expressed in all cases, 
while TAp63 in 18 out of 20 (90%) cases. The short isoforms appeared only in cases of 
invasive carcinomas, while were absent in the two DIN/DCIS. Specifically ΔNp73L was 
expressed in 4 out of 18 (22%) cases and d4TAp63 in 11 out of 18 (61%) cases of IBC. 
1. p63 short isoforms 
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1.3.3 Sequencing 
In all cases the sequences obtained from “normal band” (normal isoforms, ΔNp63 
and TAp63), revealed the last aminoacid of exon 3 (Tryptophane) linked to the complete 
sequence of exon 4. Viceversa in IBC the electropherogram obtained from a lower band, 
revealed the last aminoacid of exon 3 linked to the complete sequence of exon 5, 
indicating that exon 4 was spliced out (Figs. 1.5 and 1.6). 
 
 
Figure 1.5. Gel of p63 isoforms. Lower bands represent the short isoforms (lacking exon 
4), while upper bands represent the full-length isoforms. Ctrls: controls; MW: molecular 
weight marker (ΔNA molecular weight marker VI, Roche Diagnostics Corporation, IN, 
USA). 
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Figure 1.6: Electropherogram of bands obtained after nested PCR. (A) Sequences of full-
lenght (TAp63) and (B) shorter isoform (d4TAp63). In shorter isoform sequence, it is possible to 
observe as Tryptophan (last aminoacid of exon 3) is followed by the sequence of exon 5 (starting 
with a Tyrosine) and not by a Proline (first aminoacid of exon 4). 
 
 
1.3.4 Relation between nested PCR results and clinical, morphological and  
immunohistochemical data 
The four invasive carcinomas presenting the ΔNp73L isoform were histologically 
diagnosed as IDC in two cases (grade III and grade II respectively) and ILC, pleomorphic 
type (grade III) in the remaining two. Three out of these 4 (75%) cases that expressed 
ΔNp73L, had lymph node metastases at presentation (Table 1.4). 
1. p63 short isoforms 
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It is pertinent to emphasize that immunohistochemistry was less sensitive as p63 
positivity was detected in the two cases of IDC only (table 4, cases 8 and 15). 
d4TAp63 (Table 1.4) isoform was observed in 11 out of 18 (61%) cases of invasive 
carcinoma which were two ILC (cases 1, 5) and nine IDC (cases 7, 8, 11, 13, 14-18). Six 
cases (55%) had lymph node metastases. On immunohistochemistry p63 positivity was 
observed in four cases (cases 8, 13, 14, 15). 
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1.4 DISCUSSION AND CONCLUSIONS 
 
In the present study 40 specimens from normal breast, benign lesions, DIN/DCIS, and 
invasive carcinomas were analyzed by immunohistochemistry and RT-PCR (Reverse 
Transcriptase-PCR) in order to disclose the patterns of p63 expression.  
Immunopositivity for p63 in invasive carcinomas of the breast has been described in 
myoepithelial, metaplastic and some salivary–like carcinomas [39, 40, 45, 46]. p63 was 
found to be positive in 55.5% of basal-like carcinoma of the breast [47], while a much 
lower positivity that ranged from 0.6% to 19.5% was observed in “ordinary” luminal type 
invasive carcinomas [21, 45, 47]. The present cases were all luminal type invasive 
carcinomas [44, 46], negative for CK14. With the exception of four cases that contained 
rare positive cells and two in which p63 positivity was found in 5% and 10% of the 
neoplastic cells, the remaining invasive carcinomas were devoid of p63 immunostaining. 
In normal breast, in benign lesions and in the 2 cases of DIN/DCIS 
immunohistochemistry for p63 stained myoepithelial cells only. In addition the full-
length isoforms (with exon 4), ΔNp63 and TAp63, were detected at molecular level, 
suggesting that the full length isoforms detected by PCR are most probably expressed by 
normal myoepithelial cells.  
On the contrary, the full length isoforms were consistently found at molecular level in all 
invasive carcinomas at variance with immunohistochemistry that stained for p63 only 
occasional cells in 6 cases. These discrepant data between molecular and 
immunohistochemical techniques are more likely consequent to the fact that PCR is a 
sensitive technique that reveals isoforms even if expressed in small quantity. 
Invasive carcinomas in addition showed in 12 cases one of the two or both short 
isoforms (ΔNp73L and d4TAp63, lacking exon 4). This parallel other malignant lesions 
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from other organs such as salivary gland carcinomas [28] and squamous cell carcinomas 
of oral cavity [14, 48], where the two short-isoforms appear only in tumoural cells. 
Therefore, it seems from the present data that IBC with luminal phenotype can express 
p63, especially in its altered forms. The fact that short isoforms were not found in 
DIN/DCIS (admittedly two cases only) might indicate that these same isoforms are sign 
of tumoural progression. 
In conclusion it appears that: 
1- The full-length isoforms can be detected in non neoplastic and neoplastic lesions 
at molecular level. 
2- The short isoforms that lack exon 4 are only present in the neoplastic cells of 
invasive carcinomas. 
3- Presence of p63 in invasive carcinomas of luminal type as seen at molecular 
level suggests caution to include p63 as a specific marker of basal-like 
carcinomas.
1. p63 short isoforms 
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2. GENETIC HETHEROGENEITY IN METAPLASTIC BREAST CARCINOMAS 
 
2.1 INTRODUCTION 
 
2.1.1 Metaplastic Breast carcinoma 
Most benign and malignant tumours of the breast arise from glandular epithelium. 
However, in some cases glandular epithelium differentiates into nonglandular tissue, a 
process called metaplasia. Although both the basis and true incidence of this process is 
unknown because it often is not reported when it occurs microscopically, such 
differentiation may become such a significant component of the tumour as to characterize 
it as a distinct entity for purposes of diagnosis and treatment. Oberman proposed the term 
metaplastic carcinoma to account for all mixed carcinomas of the breast. Metaplastic 
carcinomas of the breast are a heterogeneous group of neoplasms which exhibit varied 
patterns of metaplasia and differentiation along multiple cell lines [1]. 
Histopathological findings. Metaplastic carcinoma comprises a heterogeneous group 
of neoplasms generally characterized by an intimate admixture of adenocarcinoma with 
areas of spindle, squamous, chondroid, and osseous differentiation; the metaplastic 
spindle and squamous carcinomas may be present in pure form, without any recognizable 
adenocarcinoma component. Either purely epithelial or with a mesenchymal component, 
classification according to the apparent phenotype of the tomour is now required and 
immunohistochemical confirmation is necessary (Table 2.1) [2]. 
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CLASSIFICATION OF METAPLASTIC CARCINOMA 
Purely Epithelial Carcinoma  
Squamous Carcinoma  
Large cell type, keratinizing or nonkeratinizing  
Squamous carcinoma with spindle cell metaplasia  
(with or without acantholytic changes)  
Adenosquamous Carcinoma  
High Grade  
Low Grade  
Adenocarcinoma with Spindle Cell Metaplasia 
Mixed Epithelial and Mesenchymal Carcinoma  
Carcinoma with chondroid differentiation 
Carcinoma with osseous differentiation  
Carcinoma with rhabdomyosarcomatous component  
Carcinosarcoma  
Table 2.1: Classification of Metaplastic Carcinomas 
 
In FNA (Fine Needle Aspiration) smears, only 57% of cases show ductal carcinoma 
and metaplastic components. Thus, in almost one half of cases, the diagnosis is not 
possible by FNA [3, 4]. The diagnosis of metaplastic breast carcinoma often requires 
immunohistochemistry with a cytokeratin panel to distinguish such cases from phyllodes 
tumours, primary sarcomas, and fibromatoses [5] 
Clinical findings. Metaplastic carcinoma of the breast occurs in less than 5% of 
breast carcinoma patients [6] and has an uncertain prognostic significance. Tavassoli [7] 
reported an incidence of less than 1% and Smith et al. [8] 0.02% for this type of tumour. 
First described by Huvos et al. [9], the average age of the patients with metaplastic 
carcinoma, the clinical presentation, and the overall 5-year survival rate of 55% were 
similar to such findings in patient with regular infiltrating duct carcinoma. When patients 
with tumours showing spindle and squamous differentiation were combined in one group, 
they had a 63 percent 5-year survival rate and 56 percent of the women had axillary node 
metastases. Only 19 percent of patients with neoplasms showing osseous and chondroid 
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differentiation had axillary node metastases and their 5-year survival rate was 28 percent 
[2]. 
Oberman suggested that all these tumours be categorized as metaplastic carcinoma of 
the breast, deemphasizing whether the metaplastic component is of mesenchymal or 
epithelial origin [6]. 
Metaplastic carcinomas are usually not associated with oestrogen or progesterone 
receptors. As in other carcinomas, tumour size appears to be important. Axillary lymph 
node involvement is reported in 6% [10], 26% [11], and 25– 30% [12] of cases. As with 
other breast carcinomas, these tumours have a high metastatic potential despite frequently 
negative lymph nodes, as observed in several studies [11, 13, 14]. Most published data on 
metastases of metaplastic carcinoma have shown haematogenous (lung and bone) 
metastases rather than lymphatic spread [6, 10, 15]. 
Prognosis. The precise histogenesis and prognosis of metaplastic carcinomas is still 
poorly understood, although some studies have shown a good prognosis in a relatively 
short follow-up period [16, 17]. Duration of symptoms, TNM stage, tumour size, and 
axillary nodal status were significant prognostic factors of survival [2]. However, a Mayo 
Clinic study showed that only age and prior oestrogen use were found to be significantly 
associated with either free or overall survival [14]. Clinic were more commonly (87%) 
node negative at presentation, and had a 3-year overall survival rate of 71%. Women 
older than 60 years at diagnosis were found to have an increased disease-free survival 
time compared to those less than 60 years old, but no difference in overall survival was 
found. About 50% of the women developed metastases. 
Therapy. There is little information available on the efficacy of current therapies in 
the management of metaplastic carcinoma. Most studies that have addressed treatment of 
these lesions have not separated the subtypes, unfortunately. Anyway it appears that 
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metaplastic breast carcinomas are less responsive to therapy with the conventional 
regimens used for typical adenocarcinoma of the breast [2]. This is particularly true in 
case of metastatic disease. Rayson et al. reported the median survival from detection of 
metastasic disease as 8 months, using systemic treatment [14]. Wargotz et al. [10], also 
found no survival advantage for patients treated either by chemotherapy or radiation for 
distant metastases. These data suggest that patients with metastatic metaplastic breast 
carcinoma may be candidates for innovative chemotherapeutic regimens as first-line 
therapy for metastatic disease [2]. Based on a smaller number of cases, others have 
advocated that surgical and adjuvant therapy should follow the guidelines used for 
common breast cancers. 
 
2.1.2 Intra-tumour heterogeneity 
Several lines of evidence indicate that cancers may be composed of multiple sub-
modal clones harbouring the same initiating genetic changes followed by the acquisition 
of additional divergent genetic hits [18]. The existence of such non-modal populations 
harbouring distinct genetic aberrations may explain the phenotypic diversity observed 
within a given tumour [19]. Furthermore, disease progression and resistance to chemo- 
and targeted therapies may occur due to the selection of sub-clones harbouring specific 
genetic aberrations that render them more aggressive and insensitive to treatment [19-21]. 
Apart from the existence of genetically distinctive non-modal populations, intra-
tumour phenotypic diversity can be explained by non-genetic mechanisms, including 
epigenetic regulation of genes and molecular networks, epithelial-to-mesenchymal 
transition, interaction with specific niches and tumour microenvironment [19, 22-25], and 
by the ‘cancer stem cell’ hypothesis [26-30]. This hypothesis proposes that the intra-
tumour heterogeneity stems from and is maintained by a small population of cells (the so-
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called ‘cancer stem cells’), which give rise to more differentiated cells and thus create the 
phenotypic diversity of tumours [19, 26-28]. 
Intra-tumour morphological heterogeneity is not uncommon in breast cancer. It can 
often be appreciated in mixed carcinomas, which are characterised by distinct histological 
growth patterns admixed together, and in metaplastic breast carcinomas, which are 
defined by the presence of areas composed of cells with divergent morphological 
differentiation, towards squamous epithelium or mesenchymal elements [31]. The vast 
majority of metaplastic breast carcinomas are of basal-like molecular subtype (>90%) 
[31, 32] and harbour TP53 mutations in >70% of the cases [33]. 
 
2.1.3 Micro-Array CGH 
Microarray-based comparative genomic hybridization (aCGH) was developed in the 
late 1990s and brought with it the advantages of rapid, high-resolution screening of entire 
genomes. 
Microarray-based CGH (array-CGH, aCGH) is a technique that provides detailed 
characterisation of numerical DNA aberrations in a genome-wide fashion [34], such as 
aneuploidy, unbalanced translocations, amplifications and deletions [35] 
From a technical point of view, a test (tumour) and reference (normal genomic) DNA 
are differentially labelled with green and red fluorescent dyes, mixed in a 1:1 ratio in the 
presence of human cot-1 DNA in order to block repetitive sequences, and co-hybridized 
to a representation of the genome, i.e. a platform composed of DNA inserts spaced 
throughout the whole genome in predefined intervals. Specialized image analysis 
softwares coupled with a dedicated scanner are then used to capture the images and 
convert hybridization intensity data to a red–green ratio profile [34]. 
 
2.1 Introduction 
44 | 
 
 
Figure 2.1: Schematic representation of the microarray-CGH technique. The test (tumour) and the 
reference (normal genomic) DNA are differentially labelled with green and red fluorescent dyes, mixed in 
a 1:1 ratio in the presence of human cot-1 DNA (to block repetitive sequences), and finally co-hybridized 
to a chip of a given platform. Specialized image analysis softwares coupled with a dedicated scanner are 
then used to capture the images and convert hybridization intensity data to a red–green ratio profile. 
Representation of the genomic changes of a given sample can be visualised either throughout the genome 
(genome plot) or chromosome by chromosome (see chromosome plot on the right hand side). 
 
 
Deviations from a 1:1 ratio are counted as a significant change in DNA copy number 
when defined thresholds are crossed and statistical verification applied. 
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Figure 2.2: Example of a genome plot illustrating the genomic profile of a breast cancer using a BAC array 
platform. Log2 ratios are plotted on the Y axis against each clone according to genomic location on the X 
axis. 
 
 
A plethora of different aCGH platforms are currently available, most of them can be 
obtained commercially and each of them displays both advantages and drawbacks (for a 
comprehensive discussion of these technologies see [36]). The platform used in the 
present study is a BAC array platform, ie a platform composed of bacterial artificial 
chromosomes (BACs) containing sequence-verified, fluorescent in situ hybridization 
(FISH)-mapped DNA inserts spaced throughout the whole genome in predefined 
intervals. Bacterial artificial chromosomes are large-insert genomic clones which have 
been widely used in aCGH studies [37-39]. BAC probes vary in length from 100 to 200 
kb and the resolution of each BAC array is defined by the number of unique probes it 
contains. The probe content of genome-wide BAC arrays range from a few hundreds to 
approximately 32,000 unique elements (tiling path array, as the one used in this study). 
Tiling path arrays (that is, arrays where each BAC overlaps with its contiguous BACs) 
provide a resolution of up to approximately 50 kb, given that a genomic change can only 
be detected if it is sufficiently big to significantly change the hybridisation intensity in 
one of the channels (that is, change the red:green ratios). These platforms provide 
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sufficiently intense signals for the detection of single-copy number changes, are able to 
accurately define the boundaries of genomic aberrations and, importantly, can be readily 
applied to DNA extracted from archival formalin-fixed paraffin-embedded (FFPE) tissue 
as well [40, 41]. One of the main drawbacks with BAC arrays is their limited availability 
from commercial sources and the expensive and highly labour-intensive in-house 
production. 
 
2.1.4 Array - CGH and the identification of new targets in breast cancer 
In the past years conventional and array-based CGH has helped characterise the 
relationship between putative breast cancer precursors and invasive carcinoma, define the 
molecular genetic pathways of breast cancer, as well as the typical genetic changes of 
different types of breast cancers, but most importantly has contributed to the 
identification of genomic regions harbouring oncogenes that might be activated in 
specific breast cancer histological subtypes [34, 42]. Putative therapeutic targets for 
specific subgroups of breast cancer have been recently found. As an example, a recurrent 
amplification of 8p11.2-p12 has been identified in classic lobular breast carcinomas [43]. 
By applying array CGH and expression analysis to breast cancer cell lines, the cell line 
MDA-MB-134 that harbours a simple karyorype, deletion of 16q and E-cadherin 
inactivation (hallmark feaures of lobular breast carcinomas) was identified. In addition, 
this cell line displayed an amplification on 8p11.2-p12 remarkably similar to that found in 
lobular carcinomas. By subjecting the MDA-MB-134 cell line and control cell lines to 
gene expression profiling, FGFR1 was identified as a putative amplicon driver of the 
region. Most importantly, functional analysis with RNA interference and with chemical 
compounds against FGFR1 revealed that MDA-MB-134 cells are dependent on signalling 
by the tyrosine kinase receptor. These findings suggest FGFR1 may be a therapeutic 
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target in lobular carcinomas. Subsequent analysis of a large series of ER-positive cancers 
demonstrated that FGFR1 amplification is also an independent predictor of outcome in 
this group of cancers [44]. 
 
A putative therapeutic target has recently identified also in metaplastic carcinomas, a 
specific subtype of basal-like carcinomas, known not to express hormone receptors or 
HER2, to have a poor prognosis and not to respond to conventional chemotherapy 
regimens. Hence, the identification of novel therapeutic targets for these tumours would 
be invaluable. Approximately 2/3 of metaplastic breast cancers show EGFR 
overexpression, however, EGFR overexpression per se has been reported to be a poor 
predictor of response to specific therapy such as EGFR tyrosine kinase inhibitors; on the 
other hand, EGFR activating mutations and/ or gene amplification have been shown to be 
associated with increased response to these agents [45-49]. The presence of EGFR gene 
mutations and amplification has been recently investigated and EGFR gene amplification 
was found in approximately 25% of EGFR overexpressing cases, whereas no activating 
mutations could be detected. Although overexpression was much more pervasive than 
gene amplification, a significant correlation between EGFR amplification and 
overexpression was observed [50]. Currently, studies testing whether EGFR tyrosine 
kinase inhibitors are effective in EGFR amplified breast cancer models are currently 
being carried on. If addiction to EGFR signalling will be proven in this subgroup of breast 
cancers, EGFR inihibitors or antibodies against EGFR may be emerge as a novel targeted 
therapy for these patients.  
The above markers identified first by aCGH are not ready for prime time as yet, 
however, these studies provide an algorithm for the identification of putative oncogenes 
that can be targeted based on the principle of oncogene addiction (which proposes that 
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although cancers are affected by multiple genetic and epigenetic abnormalities, they are 
dependent on one or few genes for maintenance of the malignant phenotype [51]) and 
they exemplify the way molecular genetics may contribute to individualised therapy for 
breast cancer patients. Furthermore, given that the expression of the above genes seems to 
be driven by an increase in copy number, the identification of patients who may benefit 
from drugs targeting FGFR1 or EGFR can be performed by methods that are more 
palatable for diagnostic pathologists, such as a combination of in situ hybridisation, either 
chromogenic or fluorescent, and immunohistochemical analysis. 
To determine the existence of intra-tumour genetic heterogeneity in breast cancers 
and whether areas with distinct morphological features in a given tumour might be 
underpinned by distinct patterns of genetic aberrations, we analysed six metaplastic breast 
carcinomas with at least two morphologically distinct components. In this proof of 
principle study, the components of each case were microdissected separately and 
subjected to high-resolution microarray-based comparative genomic hybridisation 
(aCGH) analysis, using a validated 32K bacterial artificial chromosome (BAC) array 
platform [52], followed by immunohistochemistry. Although in the majority of the cases, 
the distinct components displayed similar genomic and immunophenotypic profiles, in 
two cases our analysis revealed significant differences, with specific genetic alterations in 
the distinct components, providing direct evidence of intra-tumour genetic heterogeneity. 
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2.2 MATERIAL AND METHODS 
 
2.2.1 Case selection 
47 cases of metaplastic breast carcinomas from the pathology files of the Royal 
Marsden Hospital, London, UK were retrieved. All cases were reviewed by two 
pathologists and only cases with ≥2 morphologically distinct components, which were of 
sufficient dimensions to be microdissected independently, were retrieved. Out of the 47 
cases, 9 had areas that were of sufficient dimensions to be independently microdissected 
without any contamination by cells of the other component(s); however 3 of these cases 
were excluded due to DNA of insufficient yield or quality for downstream analysis. The 
final series included in this study comprised six metaplastic breast carcinomas with at 
least two morphologically distinct components, of which one also had a matched axillary 
lymph node metastasis present at time of diagnosis. 
All morphologically distinct components but the chondroid component of case 4 and 
the lobular component of case 5 were of histological grade 3 as defined by the 
Nottingham grading system [53] (Table 2.2). None of the patients received chemotherapy 
prior to the excision of the primary tumours and lymph node metastasis. 
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Case  Component Histological 
Grade° 
1 chondroid 3 
spindle 3 
2 
chondroid 3 
spindle 3 
rhabdoid 3 
3 epithelial 3 
chondroid 3 
4 chondroid 2 
spindle 3 
5 squamous 3 
lobular 2 
6 
ductal 3 
squamous 3 
spindle 3 
metastasis 3 
Table 2.2: Morphologically distinct components of six 
metaplastic breast carcinomas. ° Nottingham grading system.  
 
2.2.2 Microdissection and Nucleic Acids Extraction 
The distinct components from each case were separately microdissected to ensure 
>90% of purity of neoplastic cells. Microdissection was performed with a sterile needle 
under a stereomicroscope (Olympus SZ61, Tokyo, Japan) from ten consecutive 8 μm 
thick representative sections of the tumours stained with nuclear fast red as previously 
described [54]. In addition, we extracted DNA from ten consecutive sections of 
morphologically confirmed adjacent normal breast from each case. DNA was extracted 
using the DNeasy Kit (Qiagen Ltd, Crawley, UK) according to the manufacturer’s 
recommendations. DNA concentration was measured with the PicoGreen® assay as per 
the manufacturer’s instructions (Invitrogen, Paisley, UK) [54]. RNA from case 6 was 
extracted from whole tissue sections characterised by only one of the distinct 
morphological components with RNeasy FFPE Kit (Qiagen Ltd, Crawley, UK) according 
to the manufacturer’s recommendations. 
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2.2.3 Microarray Comparative Genomic Hybridisation 
The 32K BAC re-array collection (CHORI) tiling path aCGH platform used for this 
study was constructed at the Breakthrough Breast Cancer Research Centre (Institute of 
Cancer Research, London - UK). This platform comprises >32,000 clones, spotted onto 
Corning GAPSII coated glass slides (Corning, NY, USA) (Fig. 2.3). This type of BAC 
array platform has been shown to be as robust as and to have comparable resolution with 
high density oligonucleotide arrays [55]. 
 
Figure 2.3: Microarray chip pertaining 
to the 32K BAC re-array collection 
(CHORI) tiling path aCGH platform 
constructed in the Breakthrough Breast 
Cancer Research Centre. The chip 
contains >32,000 clones, spotted onto 
Corning GAPSII coated glass slides 
(Corning, NY, USA). The images are 
courtesy of the Breakthrough Breast 
Cancer Research Centre (London, UK). 
 
 
 
 
DNA labelling and array hybridisation. No whole genome DNA amplification was 
performed. DNA labelling, array hybridisations and image acquisition were performed as 
follows [56, 57]: reference (normal DNA extracted from blood lymphocytes pooled from 
24 females) and tumour DNA samples (300 ng aliquots) were labelled with Cy3- or Cy5-
conjugated dCTP respectively (Amersham Biosciences, Buckinghamshire, UK) using 
random primed BioPrime DNA labelling (Invitrogen Life Technologies) according to the 
manufacturer's protocol, modified to incorporate 1.0 mM Cy dye, 0.6 mM dCTP and 1.2 
mM dATP, dGTP and dTTP. After labelling at 37 °C for 16 h, non-incorporated reaction 
constituents were removed by MinElute Reaction Cleanup (Qiagen Ltd, Crawley, UK). 
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Labelled reference and tumour DNA were co-ethanol precipitated with 100 µg human 
Cot-1 DNA (Invitrogen Life Technologies) and re-suspended in 45 µl hybridisation 
buffer (50% deionised formamide, 10% w/v dextran sulphate, 2× SSC, 2% SDS, 20 µg 
yeast tRNA). Labelled DNA was denatured at 70 °C for 15 min, followed by a 30 min 
incubation at 37°C to allow blocking of repetitive sequences by human Cot-1 DNA. 
Denatured DNA samples were applied to the microarray under a coverslip and hybridised 
at 37 °C for 18 h. After hybridisation, the coverslips were removed by washing slides in 
2× SSC/1% SDS for 15 min at 45 °C. Slides were then washed in 50% deionised 
formamide/2× SSC for 15 min at 45 °C, followed by 2× SSC/1% SDS for 30 min at 45 
°C and twice in 0.2× SSC for 15 min at room temperature. After washing, the arrays were 
dried by centrifugation at 2000 r.p.m. for 2 min. aCGH slides were scanned using an 
Axon 4000B scanner (Axon Instruments, Burlingame, CA, USA) and images were 
processed using Genepix Pro 4.0 image analysis software (Axon Instruments) (Fig. 2.4). 
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Figure 2.4: Screen shot of a chip during scanning using Axon 4000B scanner and Genepix Pro 4.0 
image analysis software (Axon Instruments). 
 
Data analysis. aCGH data were pre-processed and analysed using an in-house R 
script (BACE.R) in R version 2.8.0 [58, 59]. After filtering polymorphic BACs, a final 
dataset of 31544 clones with unambiguous mapping information according to the March 
2006 build (hg18) of the human genome (http://www.ensembl.org) was smoothed using 
the circular binary segmentation (cbs) algorithm [56, 60]. A categorical analysis was 
applied to the BACs after classifying them as representing amplification (>0.45), gain 
(>0.08 and ≤0.45), loss (<-0.08), or no-change according to their cbs-smoothed Log2 ratio 
values [56, 57]. Threshold values were chosen to correspond to three standard deviations 
of the normal ratios obtained from the filtered clones mapping to chromosomes 1-22, 
assessed in multiple hybridisations between DNA extracted from a pool of male and 
female blood donors as previously described [54]. Low level gain was defined as a 
smoothed Log2 ratio of between 0.12 and 0.45, corresponding to approximately 3-5 
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copies of the locus, whilst gene amplification was defined as having a Log2 ratio > 0.45, 
corresponding to more than 5 copies. 
 
2.2.4 Hierarchical Cluster Analysis 
Unsupervised hierarchical cluster analysis was performed using the hclust function 
from Bioconductor R aCGH package, using aCGH smoothed ratios or categorical data 
from the filtered set of 31544 clones as the distance and Ward’s clustering algorithm [61, 
62]. 
 
2.2.5 In Situ Hybridisation 
Chromogenic (CISH) and fluorescence in situ hybridisation (FISH) were carried out 
for validation of aCGH results in selected cases. Ready-to-use digoxigenin-labelled 
SpotLight amplification probes for the epidermal growth factor receptor gene (EGFR) 
and HER2 (Invitrogen, Paisley, UK) and biotin-labelled in-house made probes for 3q24, 
8p11.2 and 12q14 were used. In-house probes were generated according to protocols 
described by Lambros et al. [63] and tested for their specificity. The BACs used were 
RP11-597O1 and RP11-725I19 for 3q24, RP11-104D16 for 8p11.2, and RP11-66N19, 
RP11-277A02 and RP11-549D07 for 12q14. Each BAC and probe were FISH mapped 
using slides containing normal lymphocyte metaphase spreads (Vysis Inc., Downers 
Grove, USA) and end sequencing verified using SP6 or T7 primers [63]. Tissue pre-
treatment, hybridisations and washes were performed as previously described [63]. 
Signals were counted in non-overlapping nuclei of 60 morphologically unequivocal 
neoplastic cells. Amplification was defined as the presence of gene clusters or more than 
5 signals in at least 50% of the neoplastic cells [28, 50]. 
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2.2.6 Immunohistochemistry 
Formalin-fixed, paraffin-embedded sections were cut at 3μm and mounted on silane-
coated slides. Immunohistochemistry was performed using antibodies raised against 
oestrogen receptor (ER, clone ID5, Dako, 1:40), progesterone receptor (PR, clone 
PgR636, Dako, 1:200), HER2 (Herceptest, Dako), p53 (clone DO7, Dako, 1:200) and 
‘basal-like’ markers (EGFR (clone 31G7, Invitrogen, 1:50), cytokeratin (CK) 5/6 (clone 
D5/16B4, Chemicon, 1:600), CK14 (clone LL002, Vector Labs, 1:40)). Heat induced 
antigen retrieval was employed for ER, PR, p53, CK 5/6, CK 14 and HER2 by heating the 
sections in citrate buffer pH6 either for 2 min in a pressure cooker (ER, PR and p53), for 
18 min in a microwave oven (CK 5/6 and CK 14), or for 40 min in the LabVision pre-
treatment module (HER2) [64]. Antigen retrieval for EGFR was performed using 0.1% 
pronase for 10 minutes at 37°C [50]. ER and PR were considered positive if >1% of cells 
in each distinct component displayed nuclear reactivity. For CKs, membranous or 
cytoplasmic staining in more than 1% of morphologically unequivocal neoplastic cells 
was recorded as positive. HER2 was evaluated according to current clinical guidelines 
[65] and EGFR as previously described [50]. For p53, strong nuclear staining in more 
than 50% of the neoplastic cells was recorded as positive. 
 
2.2.7 p53 Mutation Analysis 
Sequencing of known mutation hotspots of TP53 on exons 5-9 [66] was performed in 
selected cases (cases 2, 5 and 6 and matched adjacent normal breast tissues). The primers 
used for TP53 sequencing have been previously described [66] (Tab. 2.3). 50ng tumour 
DNA was amplified and sequencing reactions were carried out using the DNA 
Sequencing Kit BigDye Terminator v 1.1 Cycle Sequencing Ready Reaction Mix 
(Applied Biosystems, Warrington, UK). Sequences were analysed with Mutation 
2.2 Material and Methods 
56 | 
 
Surveyor software (Softgenetics, PA, USA). Mutations were confirmed by repeat PCR 
using the same DNA samples subjected to aCGH followed by sequencing reactions, PCR 
of DNA extracted from re-microdissected material of each component followed by 
sequencing reactions, and by sequencing forward and reverse strands. 
 
Exon Sequence 5’-3’ PCR product size, 
bp 
5                 Fw 
Rv 
CTTGTGCCCTGACTTTCAACTCTGTCTC 
270 
TGGGCAACCAGCCCTGTCGTCTCTCCA 
6                 Fw 
Rv 
CCAGGCCTCTGATTCCTCACTGATTGCTC 
202 
GCCACTGACAACCACCCTTAACCCCTC 
7                 Fw 
Rv 
GCCTCATCTTGGGCCTGTGTTATCTCC 
173 
GGCCAGTGTGCAGGGTGGCAAGTGGCTC 
8                 Fw 
Rv 
GTAGGACCTGATTTCCTTACTGCCTCTTGC 
239 
ATAACTGCACCCTTGGTCTCCTCCACCGC 
9                 Fw 
Rv 
CACTTTTATCACCTTTCCTTGCCTCTTTCC 
144 
AACTTTCCACTTGATAAGAGGTCCCAAGAC 
Table 2.3: PCR primers for p53 analysis. 
 
2.2.8 HUMARA Assay 
The HUMARA assay was performed in selected cases by DNA methylation-sensitive 
digestion followed by nested PCR. Aliquots of 200ng of tumour DNA were digested with 
10 units of HpaII restriction enzyme (New England Biolabs, Ipswich, MA, USA) at 37° 
overnight in a 20μl reaction volume. Separate aliquots of DNA were subjected to mock 
digestion without the enzyme. After incubation the restriction enzyme was inactivated at 
65° for 20 minutes according to the manufacturer’s recommendations. 5μl of digested or 
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mock-digested DNA was submitted to a nested PCR reaction [67], where the forward 
primer of the second set of PCR was 5’ FAM labelled. Primer sequences have been 
previously described by Kuijper et al. [67] (Tab. 2.4). PCR products were run on the 
Applied Biosystems 3100 Genetic Analyser (Applied Biosystems, Warrington, UK). 
 
Primers Sequence 5’-3’ 
Outer1 TGTGGGGCCTCTACGATG 
Outer3 CCGTCCAAGACCTACCGA 
Inner2 CCGAGGAGCTTTCCAGAATC 
Inner4* TACGATGGGCTTGGGGAGAA 
Table 2.4: Primers used for HUMARA assay. *: Primer 4 was fluorescently labelled with FAM. 
 
2.2.9 Quantitative real-time reverse transcriptase PCR (qRT-PCR) 
Reverse transcription of total RNA from case 6 was carried out using Superscript III 
(Invitrogen, UK). Quantitative real-time reverse transcriptase PCR (qRT-PCR) was 
performed for ERB-B2 (Applied Biosystems) using TaqMan® chemistry on the ABI 
Prism 7900HT (Applied Biosystems), using the standard curve method. In addition, two 
reference genes (TFRC and MRPL19 - Applied Biosystems) were used, having been 
previously selected as effectively normalising for degradation of RNA [68]. Target gene 
expression levels were normalised to the geometric mean of the two reference genes. 
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2.3 RESULTS 
 
2.3.1 Cases 1-4 
In cases 1 to 4, which were carcinomas with heterologous elements, composed of 
ductal, chondroid and/ or spindle areas, the morphologically distinct components 
(Figures. 2.5a, 2.5d, 2.5g) harboured strikingly similar immunohistochemical and 
genomic profiles (Figures. 2.5b, 2.5e, 2.5h; Table 2.5). All components displayed a triple 
negative phenotype (i.e. ER-, PR- and HER2-negative) and were classified as of basal-
like subtype according to a validated immunohistochemical definition [69] (Table 2.5). 
Our aCGH analysis revealed similar patterns of copy number changes between the 
components of each of these four cases (Figure 2.5), with <23% of the genomes showing 
different genetic aberrations. Pearson’s correlation, performed using smoothed aCGH 
ratios from the components of each case, revealed r values >0.75, which indicate a good 
correlation in the patterns of genetic changes displayed by the distinct components of 
each case. In case 2, the three components strongly expressed p53 protein (Table 2.5), and 
harboured an identical, tumour specific 13824 C>T TP53 mutation (Figures 2.5c, 2.5f, 
2.5i; Table 2.6) and the same pattern of X-chromosome inactivation by the HUMARA 
assay (Table 2.6), confirming their clonality. Analysis of germline DNA extracted from 
adjacent normal breast tissue from case 2 demonstrated wild-type TP53. 
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Case  Component Histological 
Grade° 
Immunohistochemical Analysis Molecular 
Subgroup* ER PR HER2 CK5/6 CK14 EGFR p53 
1 chondroid 3 - - - + + - - Basal-like 
spindle 3 - - - + + - - Basal-like 
2 
chondroid 3 - - - + + + + Basal-like 
spindle 3 - - - - - + + Basal-like 
rhabdoid 3 - - - - - + + Basal-like 
3 epithelial 3 - - - + + + + Basal-like 
chondroid 3 - - - + + + + Basal-like 
4 chondroid 2 - - - + + - - Basal-like 
spindle 3 - - - + + - - Basal-like 
Table 2.5: Histological features, immunohistochemical analysis and molecular subgroups of morphologically 
distinct components of cases 1 to 4. °Nottingham grading system. *Breast cancer molecular subtypes as defined 
by Nielsen et al. [69] criteria. ER: oestrogen receptor; CK: cytokeratin; EGFR: epidermal growth factor receptor; 
PR: progesterone receptor. 
 
 
Figure 2.5: Case 2 – Metaplastic carcinoma with heterologous elements. The distinct 
morphological components harbour remarkably similar genomic profiles and identical 13824 C>T 
TP53 gene mutation. Representative micrographs, genome plots and TP53 mutation analysis of the 
chondroid (a, b and c), spindle (d, e and f) and rhabdoid (g, h and i) components. In the genome 
plots, Log2 ratios are plotted on the Y axis against each clone according to genomic location on the 
X axis. BACs categorised as displaying genomic gains or amplification are plotted in green and 
bright green, respectively, and those categorised as regions of genomic losses are depicted in red. 
Raw: examples of similar alterations. 
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Case  Component 
TP53 Mutation Analysis HUMARA 
assay  Exon 5 Exon 6  Exon 7 Exon 8 Exon 9 
2 
chondroid WT WT WT 13824 C>T WT 
Identical 
pattern spindle WT WT WT 13824 C>T WT 
rhabdoid WT WT WT 13824 C>T WT 
normal adjacent breast WT WT WT WT WT Polyclonal 
Table 2.6: Clonality analysis between the morphologically distinct components of case 2. NP: not 
performed; WT: wild type.  
 
2.3.2 Cases 5-6 
In contrast, in case 5, an adenosquamous carcinoma composed of lobular and 
squamous components (Figures 2.6a and 2.6c), the genetic differences between the two 
components were such that only 20% of the genome harboured similar copy number 
changes. The lobular component, which was of classic variant and low histological grade, 
displayed a ‘simplex’ profile [70] with the expected copy number changes for a lobular 
breast carcinoma (i.e. concurrent 1q gain, 16p gain and 16q loss) [42] (Figure 2.6b). The 
squamous component was characterised by a complex ‘sawtooth’ genetic profile [54], 
lack of 16q loss and amplification of 7p11 (EGFR) (Fig. 2.6d). The divergent copy 
number status of the EGFR gene (i.e. no changes and amplification in the lobular and 
squamous components respectively) was further validated by chromogenic in situ 
hybridisation (Figures 2.7a and 2.7d, Table 2.9). 
Case  Component Histological 
Grade° 
Immunohistochemical Analysis Molecular 
Subgroup* ER PR HER2 CK5/6 CK14 EGFR p53 
5 squamous 3 - - - + + + - Basal-like 
Lobular 2 + + - - - - - Luminal 
6 
Ductal 3 - - 2+ + + + + HER2 
squamous 3 - - 3+ + + + + HER2 
Spindle 3 - - 1+ + - + + Basal-like 
metastasis 3 - - 1+ - - + + Basal-like 
Table 2.5: Histological features, immunohistochemical analysis and molecular subgroups of morphologically 
distinct components of cases 5 and 6. °Nottingham grading system. *Breast cancer molecular subtypes as defined by 
Nielsen et al. [69] criteria. ER: oestrogen receptor; CK: cytokeratin; EGFR: epidermal growth factor receptor; PR: 
progesterone receptor. 
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Figure 2.6: Case 5 – Genetic profiles. The two morphological distinct components harbour 
distinct genomic profiles. Representative micrographs and genome plots of the lobular (a and b) 
and squamous (c and d) components. Log2 ratios are plotted on the Y axis against each clone 
according to genomic location on the X axis. Note that the lobular component displayed a 
‘simplex’ genomic profile [70] with the typical pattern of genetic aberrations found in lobular 
cancers (i.e. concurrent 1q gain, 16p gain and 16q loss), lacked EGFR gene amplification (7p11), 
whereas the squamous component harboured a ‘sawtooth’ profile [71] with EGFR gene 
amplification in the form of large gene clusters (7p11). 
 
Immunophenotypically, each component was also distinct: whilst lobular cells 
expressed hormone receptors and lacked EGFR expression, squamous cells displayed the 
opposite pattern (Figures 2.7b-2.7c-2.7e-2.7f; Tab. 2.8). Clonality between the two 
components could not be established, as both displayed wild-type TP53 and an identical 
pattern of X-chromosome inactivation as defined by the HUMARA assay (Table 2.8). 
The distinct patterns of genetic aberrations in each component and their 
immunophenotypic differences are suggestive of either a ‘collision tumour’ (i.e. two 
distinct neoplasms affecting the same anatomical site but being clonally unrelated) or a 
tumour which originated from a single cell that acquired divergent genetic aberrations at 
an early stage of tumourigenesis leading to emergence of distinct morphological 
components. 
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Figure 2.7: Case 5 - Immunohistochemical profiles. The two morphological distinct components harbour 
distinct immunohistochemical profiles. Note that the lobular component lacked EGFR gene amplification 
(a) and overexpression (b), and displayed strong and diffuse ER expression (c), whereas the squamous 
component harboured EGFR gene amplification in the form of large gene clusters (h) and strong EGFR 
protein expression (e), and was ER negative (f). 
 
 
Case  Component 
TP53 Mutation Analysis HUMARA 
assay  Exon 5 Exon 6  Exon 7 Exon 8 Exon 9 
5 
Squamous WT WT WT WT WT Identical 
pattern Lobular WT WT WT WT WT 
normal adjacent breast WT WT WT WT WT Polyclonal 
6 
Ductal 12512 G>A NP WT WT WT 
Identical 
pattern 
Squamous 12512 G>A NP WT WT WT 
Spindle 12512G>A NP WT WT WT 
Metastasis 12512 G>A NP WT WT WT 
Table 2.8: Clonality analysis between the morphologically distinct components of case 5 and 6. NP: 
not performed; WT: wild type. 
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Case  Component EGFR 
CISH 
FISH HER2 qRT-
PCR° HER2 3q24 8p11.2 12q14 
5 
squamous AMP NP NP NP NP NP 
lobular Not AMP NP NP NP NP NP 
6 
ductal NP AMP Not AMP AMP AMP 5.01763929 
squamous NP AMP Not AMP AMP AMP 6.21651644 
spindle NP AMP AMP Not AMP 
Not 
AMP 0.54737271 
metastasis NP Heterogeneous* Not AMP 
Not 
AMP 
Not 
AMP 0.60340944 
Table 2.9: In situ hybridisation and quantitative RT-PCR analysis of morphologically distinct 
components of cases 5 and 6. *15% of neoplastic cells displayed more than 5 signals and/ or large gene 
clusters. °Arbitrary expression units. AMP: amplified; CISH: chromogenic in situ hybridisation; EGFR: 
epidermal growth factor receptor; FISH: fluorescence in situ hybridisation; Not AMP: not amplified; NP: 
not performed; qRT-PCR: quantitative reverse transcriptase PCR. 
 
Case 6, a biphasic spindle cell carcinoma, was characterised by ductal and squamous, 
and spindle cell areas (Figs. 2.8a, 2.8b, 2.8c). The three components lacked hormone 
receptors and expressed the basal markers EGFR and CK5/6. Although all components 
harboured an amplification of 17q12 encompassing the HER2 gene, HER2 
overexpression was limited to the ductal and squamous components at the protein and 
mRNA levels (Fig. 2.10; Tab. 2.9). Both epithelial components were genetically highly 
correlated (Pearson r value=0.89), shared with the spindle component similar gains, 
losses and amplification of 9p22.3 and 17q12 (HER2) (Figures 2.9a, 2.9b, 2.9c), and 
harboured an identical 12512 G>A TP53 mutation (Figure 2.10; Table 2.8) (which was 
not present in DNA extracted from adjacent normal breast tissue), providing direct 
evidence of their clonal nature. It should be noted, however, that divergent focal 
amplifications specific to each component were present, such as 3q24, 5p15, 9p24, 10q21 
and 15q23 in the spindle and 8p11.2, 12q14 and 17q23 in the squamous and ductal 
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components. Fluorescence in situ hybridisation validated the copy number status of 
HER2, 3q24, 8p11.2 and 12q14 regions in the distinct morphological components of the 
primary tumour, providing support for the robustness of our aCGH findings (Figure 2.10, 
Table 2.9) and the association between the morphologically distinct components and the 
amplifications of different genetic regions. HER2 amplification was confirmed in the 
modal population of each component of the primary tumour. Amplification of 3q24 was 
restricted to the spindle component and amplification of 8p11.2 and 12q14 was present 
only in the ductal and squamous components (Figure 2.10; Table 2.9). Taken together, 
our results suggest that the TP53 mutation and 17q12 amplification are likely to have 
been early events in the progression of this metaplastic carcinoma, which were followed 
by the acquisition of secondary genetic events. 
 
Figure 2.8: Case 6 – Metaplastic primary biphasic spindle cell carcinoma and axillary lymph node 
metastasis. Representative micrographs at low (40X) and high power (200X) magnification of the ductal (a and 
e), squamous (b and f) and spindle (c and g) components of the primary tumour and lymph node metastasis (d 
and h). 
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Figure 2.9: Case 6 – Metaplastic primary biphasic spindle cell carcinoma and 
matched axillary lymph node metastasis. The distinct morphological components 
and metastasis, albeit clonal, harbour divergent focal high-level amplifications. The 
matched lymph node metastasis has a genomic profile distinct from that of the three 
components of the primary tumour. Representative micrographs and genome plots of 
the ductal (a and b), squamous (c and d) and spindle (e and f) components and lymph 
node metastasis (g and h). Log2 ratios are plotted on the Y axis against each clone 
according to genomic location on the X axis. BACs categorised as displaying genomic 
gains or amplification are plotted in green and bright green, respectively, and those 
categorised as regions of genomic losses are depicted in red. 
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Figure 2.10: Case 6 – Immunohistochemical, in situ hybridisation and sequencing analysis revealed 
the presence of HER2 gene amplification and an identical 12512 G>A TP53 mutation in all components of 
the primary tumour (>50% of the neoplastic cells) and in the metastastic deposit (15% of the neoplastic 
cells). Each component displayed specific patterns of amplification: 3q24 amplification was restricted to the 
spindle component and amplifications of 8p11.2 and 12q14 were present only in the ductal and squamous 
components. 
 
Analysis of the axillary lymph node metastasis from this patient, which was poorly 
differentiated and composed of smaller but highly atypical and discohesive cells (Figures 
2.8d and 2.8h); we established its clonal nature with the primary tumour, as it harboured a 
12512 G>A TP53 mutation and inactivation of the same chromosome X (Fig. 2.10; Tab. 
2.8). Importantly, the metastatic deposit harboured specific genetic aberrations (Fig. 
2.9d), including focal high-level amplifications of 5p15, 6p24, 9q34, 19q13 and 
Xq28,which were not present in the modal populations of the ductal, squamous and 
spindle components. aCGH revealed a lower level of 17q12 amplification in the 
metastatic deposit (Figure 2.9d) when compared to that of components of the primary 
tumour (Figures 2.9a, 2.9b, 2.9c). Fluorescence in situ hybridisation with HER2 probes 
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demonstrated that the metastasis was composed of a mosaic of cells with (15%) and 
without (85%) HER2 gene amplification (as defined by >5 copies in the nucleus of each 
neoplastic cell) and lacked HER2 mRNA and protein expression (Figure 2.10; Table 2.9). 
Our results could imply that this metastasis might have originated from a malignant clone 
that did not harbour HER2 gene amplification and that a non-modal neoplastic population 
in the lymph node acquired this amplification over time independently, recapitulating the 
genetic events of the primary tumour. In fact, some studies have suggested that 
metastases may occur early during carcinogenesis and follow a distinct clonal progression 
[72, 73]. This is unlikely, however, as the breakpoints of 17q12 amplification in the 
primary tumour components and metastatic deposit were identical. Alternatively, the 
modal population of metastatic cells either lost this amplification, as HER2 was not 
expressed in any of the metastatic cells, or the metastasis was composed of multiple 
neoplastic clones from the primary tumour that drained to the same lymph node over 
time, one of which lacked HER2 gene amplification. 
 
2.3.3 Cluster Analysis 
We further evaluated the genetic similarities between the 15 morphologically distinct 
components of the six studied cases by unsupervised hierarchical clustering with the 
aCGH data (Figure 2.11). As expected, the distinct components of cases 1 to 4 clustered 
together, underlining the high similarity at the genomic level and clonal relationship 
between the components. In contrast, the lobular and squamous components of case 5, 
which had been found to display different genetic profiles (i.e. ‘simplex’ vs. ‘sawtooth’) 
including an EGFR amplification in the squamous component, clustered separately. 
Although the primary tumour components of case 6 and the axillary lymph node 
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metastasis clustered in the same branch, the ductal, squamous and spindle components of 
the primary tumour were more similar to each other than to the metastasis. 
 
 
 
 
Figure 2.11: Unsupervised hierarchical cluster analysis. Hierarchical clustering of 15 morphologically 
distinct components of six metaplastic breast carcinomas performed using microarray comparative genomic 
hybridisation cbs smoothed ratios (a) and categorical data (i.e. losses, no change, gain and amplification) (b) 
derived from the filtered set of 31544 clones. 
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2.4. DISCUSSION AND CONCLUSIONS 
 
Our results indicate that at least some breast cancers are composed of multiple non-
modal populations of clonally related cells and provide evidence of clonal evolution in 
breast cancer. 
Intra-tumour phenotypic heterogeneity can be explained by several genetic and non-
genetic mechanisms [19, 22, 28, 30, 75-77]. The distinct morphological features of cases 
5 and 6 were coincidental with the copy number changes detected by aCGH, suggesting 
that, in these cases, genetic heterogeneity may have driven the phenotypic diversity. In 
cases 1 to 4, no significant differences in copy number aberrations were observed in the 
distinct morphological components. It is plausible that using techniques with a higher 
resolution, such as massively parallel sequencing, one could detect specific mutations or 
structural somatic rearrangements that would underpin the histological differences [78]. 
Alternatively, the phenotypic diversity observed in those cases may be explained by 
epigenetic changes, interaction with the tumour microenvironment[19, 22, 23] or by the 
plasticity of cancer stem cells [26-29]. Gene expression studies have recently suggested 
that a subgroup of sarcomatoid breast cancers may be of ‘claudin-low’ subtype, which has 
features of stem cells and epithelial-mesenchymal transition [79]. 
Moreover, our results suggest that the methods that detect only the genetic 
aberrations present in the modal population of cancer cells in a given tumour may not be 
sufficient to identify all of its drivers. Although the prevalence of the phenomena 
illustrated by cases 5 and 6 needs to be determined in a large collection of tumours, our 
findings have important implications for a successful implementation of targeted 
therapies in clinical practice, in particular those that target genes whose activation is 
primarily mediated by a genetic hit. Furthermore, analysis of a single sample at a given 
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moment (e.g. primary tumour prior to the administration of adjuvant systemic therapy) 
may not provide a complete assessment of the genomic profile of the tumour and, 
therefore, may not be sufficient to determine the sensitivity of disseminated cells to a 
given agent. As demonstrated in one of the cases analysed in this study, acquisition of 
specific high level amplifications may occasionally only be detectable in the metastatic 
deposits. In this proof of principle study based on high resolution genome-wide genetic 
analysis of morphologically distinct components of metaplastic breast carcinomas, we 
demonstrate that at least some breast cancers are composed of multiple non-modal 
populations of clonally related cells and provide direct evidence of intra-tumour genetic 
heterogeneity in breast cancer. In agreement with our results, previous studies using 
conventional comparative genomic hybridisation or loss of heterozygosity techniques 
have described the existence of intra-tumour heterogeneity in a significant proportion of 
breast cancers [74, 80, 81] and the analyses of matched ductal carcinoma in situ and 
invasive carcinoma or matched invasive carcinoma and lymph node metastases [74] have 
also demonstrated genetic divergence between the matched lesions. In contrast with 
previous studies, however, we focused on the phenotypic heterogeneity within each 
tumour to guide the selection of the distinct samples from a given tumour. It should be 
noted that here we have performed an extensive microdissection of each component to 
obtain sufficient DNA, avoiding the use of whole genome DNA amplification. 
Intra-tumour phenotypic heterogeneity can be explained by several genetic and non-
genetic mechanisms [19, 75]. Our results suggest that the intra-tumour morphological 
diversity of cases 1 to 4 may be caused by genetic aberrations other than changes in copy 
number of specific genes (i.e. gene mutations or balanced somatic rearrangements), 
epigenetic changes or interaction with the tumour microenvironment [19, 22, 23]. 
Alternatively, the intra-tumour phenotypic diversity of these cancers may be attributable 
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to ‘cancer stem cells’ [26-29]. In fact, gene expression studies have shown that 
metaplastic sarcomatoid breast cancers may be of ‘claudin-low’ subtype, which has 
features of stem cells and epithelial-mesenchymal transition [82]. In contrast, the distinct 
morphological features of cases 5 and 6 were coincidental with the copy number changes 
detected by aCGH, suggesting that, in these cases, genetic heterogeneity may have driven 
the phenotypic diversity. 
In conclusion, this proof of principle study provides direct evidence that at least some 
types of breast cancers are composed of multiple non-modal clones harbouring distinct 
genetic aberrations, which at least in some cases are coincidental with and may underpin 
the morphological heterogeneity of breast cancers. Given that aCGH is only suited to 
detect clonal copy number aberrations, the existence of subclones with distinct genetic 
aberrations within a given tumour and the differences in the genetic aberrations in the 
primary lesion and metastatic deposit of a metaplastic breast cancer provide evidence that 
the acquisition of distinct genetic aberrations is associated with and may lead to distinct 
phenotypes and disease progression. However, we cannot rule out that an even greater 
genetic heterogeneity, not detectable by aCGH analysis (i.e. structural genetic aberrations 
and base pair changes) may exist in breast cancers. Moreover, our results suggest that the 
intra-tumour complexity of breast cancer genomes is greater than previously anticipated 
and that methods that detect only the genetic aberrations present in the modal population 
of cancer cells in a given tumour may not be sufficient to identify all of its drivers. 
Although the prevalence of the phenomena illustrated by cases 5 and 6 needs to be 
determined in a large collection of tumours, our findings have important implications for 
a successful implementation of targeted therapies in clinical practice, in particular those 
that target genes whose activation is primarily mediated by a genetic hit. Furthermore, 
analysis of a single sample at a given point in time (e.g. primary tumour prior to the 
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administration of adjuvant systemic therapy) may not provide a complete assessment of 
the genomic profile of the tumour and, therefore, may not be sufficient to determine the 
sensitivity of disseminated cells to a given agent. As demonstrated in one of the cases 
analysed here, acquisition of specific high-level amplifications may occasionally only be 
detectable in the metastatic deposits. 
2. Metaplastic heterogenicity 
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3. ONCOCYTIC BREAST CARCINOMAS 
 
3.1 INTRODUCTION 
 
Pink cells are characterised by wide, eosinophilic granular cytoplasm. The “pink cells 
carcinoma” could be grouped in four different ways: 
 
1. Apocrine: incidence of 0.3-4%. They are positive for GCDFP-15 and androgen. 
Negative for Bcl2, oestrogen and progesterone. The aggregation is due to secrete 
granules. 
2. Neuroendocrine: incidence of 2-5%. Characterised by positivity to neuroendocrine 
markers (in more than 50% of the cells) and to oestrogen, progesterone and 
GCDFP-15. The characteristic aggregation is due to neurosecrete granules. 
3. Acinic: very rare histotype. They are positive for amylase, lisozyme, 
chimotripsine, EMA and S-100.  The aggregates are composed by zymogen. 
4. Oncocytic (see below): very few cases described. The tumour has to be composed 
by more than 70% of oncocytic cells. An oncocytic cells has more than 60% of 
cytoplasm occupied by mitochondria. The aggregation is due to mitochondria. 
 
3.1.1 Oncocytic Tumours 
Pathologists have long been aware of the existence of a distinctive type of tumour 
composed of cells with abundant granular cytoplasm and with strong affinity for eosin. 
These peculiar cells were first described in 1898 in the thyroid gland by Askanazy and in 
the parathyroid gland by Welsh. In the 1930s Hamperl [1] coined for them the term 
"oncocyte" (from the Greek word Ογχοΰσϑαι [onkoustai], to swell) and pointed out that 
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they may give rise to tumours with corresponding morphologic features - i.e. "oncocytic 
tumours" - both benign (oncocytic adenomas) and malignant (oncocytic carcinomas). 
This term is used for those cells exhibiting the characteristic phenotype: in histology 
sections a finely granular eosinophilic cytoplasm and ultrastructurally an increase in the 
number of mitochondria. 
Oncocytic tumours represent a distinctive set of lesions with typical granular 
cytoplasmatic eosinophilia of the neoplastic cells. These cells are called oncocytes 
because of the “swollen” appearance they have as a result of this striking accumulation of 
mitochondria in more than 60% of cytoplasm [2]. With exception of thyroid and kidney, 
neoplasms composed of oncocytic cells are generally rare. The tumours – benign and 
malignant – consisting of oncocytic cells are commonly used to be designated as 
oncocytomas. The proportion of neoplastic cells exhibiting oncocytic features required to 
diagnose a tumour as oncocytic seems to vary according to the site of origin. For example 
while it is accepted that thyroid neoplasms with 75% of cells having oncocytic features 
can be confidently classified as “oncocytic”[3, 4], stricter criteria are required for a renal 
tumour to be diagnosed as oncocytic [5]. 
 
3.1.2 Mitochondria-rich and oncocytic tumours 
The accumulation of huge numbers of abnormal mitochondria as seen by electron 
microscopy and immunohistochemistry is the hallmark of oncocytic cells regardless of 
the organ of origin (thyroid, parathyroid, kidney, salivary glands) and of the benign or 
malignant nature of the lesions [6-8]. Such accumulation may also reflect a “normal” 
process; for example, the parathyroid glands normally present a variable percentage of 
oncocytic cells, most probably related with cell ageing [9]. Besides the role played by 
increased proliferation of mitochondria in the cytoplasm without cell division, it is not 
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known whether a decreased turnover of the mitochondria may also contribute to their 
accumulation in oncocytic cells [10]. Oncocyte is a descriptive term for a neoplastic or 
non-neoplastic cell stuffed with mitochondria that give a granular eosinophilic appearance 
to its large cytoplasm. In the thyroid, other terms are used: Hürthle cell transformation 
and Hürthle cell tumours [11]. Finally, there are, in some organs, tumours composed by 
oncocytes that carry specific designations (e.g. Warthin’s tumour of the salivary glands). 
The prominence of oncocytic cells in endocrine organs, salivary glands, kidney and other 
parenchymatous organs (and in their respective tumours), is in contrast to the rarity of 
oncocytic cells in the mucosa and respective tumours of the digestive and respiratory 
tract. The great majority of oncocytic tumours are epithelial derived tumours, but there 
are also on record examples of oncocytomas occurring in non-epithelial settings. Hürthle 
cells can be observed in all sorts of thyroiditis (and are prominent in Hashimoto’s 
thyroiditis of adult and elderly patients), nodular goitre, adenoma, follicular carcinoma, 
papillary carcinoma (PTC) and poorly differentiated carcinoma of the thyroid. With the 
exception of undifferentiated carcinoma, every type of benign or malignant thyroid 
tumour has its oncocytic counterpart. 
Warthin’s tumour is the second most common salivary gland tumour, arising almost 
always in the parotid gland (accounts for about 15% of all epithelial tumours of the 
parotid gland), occasionally causing pain or facial nerve paralysis. Warthin’s tumours are 
constituted by cystic spaces, lined by a double layer of oncocytic cells of questionable 
neoplastic nature that rest on a lymphoid stroma[12]. 
 
3.1.3 Oncocytic in Breast 
Only rare example of breast oncocytic carcinomas have been reported in literature 
[13, 14]. The incidence is probably underestimated because classified as “apocrine”. 
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Hystologically, these tumours are characterized by solid nests and glandular structures 
composed of round/ polygonal cells, well defined cellular borders, with finely granular, 
eosinophilic and abundant granular cytoplasm, centrally located monomorphic nuclei and 
prominent nucleoli, few mitosis [15] (Fig. 3.1). 
 
 
Figure 3.1: Haematoxylin and Eosin of an Oncocytic breast carcinoma 
 
Immunohystochemistry, obtained by the 1998 study, was positive for EMA, ER and 
negative for SMA and progesterone. 
The positivity for an anti-mitochondrial antibody was strong, granular and spread, in 
more than 70% of the cells. Moreover, the positivity was considered strong (3+) when 
present in more than 60% of cytoplasm [14]. 
We have to consider the presence of another type of cell rich in mitochondria, the 
“mitochondrial-rich cells”, described in 1960 as cells of different shape, with cytoplasm 
enriched in mitochondria grouped preferentially at base or luminal pole of the cell [16]. 
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3.1.4 Mitochondria 
Mitochondria were discovered in 1857 by Kolliker in muscle tissue (μίτος or mitos, 
thread + χονδρίον or khondrion, granule). They were aerobic microorganisms (much like 
Rickettsia) that more than a billion years ago colonized primordial eukaryotic cells 
without the ability to use oxygen. They have since adapted to a permanent symbiotic 
relationship. 
Mitochondria are semi-autonomous organelles that perform essential functions in 
cellular metabolism and the regulation of cell death. Consistent with their importance in 
metabolism, they generally occupy a major fraction of the total cell volume. In fact, 
mitochondria occupy a substantial portion of the cytoplasmic volume of eukaryotic cells, 
and they have been essential for the evolution of complex animals. 
As previously said, mitochondria arose from an endosymbiotic relationship between 
a glycolytic proto-eucaryotic cell and an oxidative bacterium. These organelles possess a 
double-membrane structure and contain their own genome along with their own 
transcription, translation, and protein assembly machinery. 
Two distinct genetic systems encode mitochondrial proteins: mitochondrial DNA 
(mtDNA) and nuclear DNA (nDNA); the vast majority are coded by nDNA and imported 
to the mitochondrion. 
The enzymes of the respiratory chain are embedded in the inner mitochondrial 
membrane, and they are essential to the process of oxidative phosphorylation, which 
generates most of the animal cell's ATP. 
However, as a consequence of proto-mitochondrial genes integrating into the nuclear 
genome throughout evolution, most mitochondrial proteins are encoded by nuclear DNA 
(nDNA) and imported into mitochondria. Although the replication of mitochondrial DNA 
(mtDNA) is not synchronized with nDNA replication, the overall number of mitochondria 
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per cell remains fairly constant for specific cell types during proliferation, suggesting that 
the generation of mitochondria is largely influenced by extra-mitochondrial signal 
transduction events. 
 
3.1.5 Genetics 
The human mtDNA (first sequenced in 1981) is a 16,569-bp, double-stranded, 
circular molecule containing 37 genes. Of these, 24 are needed for mtDNA translation (2 
ribosomal RNAs [rRNAs] and 22 transfer RNAs [tRNAs]), and 13 encode subunits of the 
respiratory chain (out of the 87 proteins required for oxidative phosphorylation): seven 
subunits of complex I (ND1, 2, 3, 4, 4L, 5, and 6), one subunit of complex III 
(cytochrome b ), three subunits of cytochrome c oxidase (COX I, II, and III), and two 
subunits of ATP synthase (A6 and A8). The mtDNA uses an alternative genetic code as 
opposed to nDNA. 
Mitochondrial genetics differs from mendelian genetics in several aspects: 
Maternal inheritance. Most of mitochondria (and most of mtDNAs) in the zygote derive 
from the ovum. Therefore, a mother carrying a mtDNA mutation passes it on to all her 
children, but only her daughters will transmit it to their progeny. 
Heteroplasmy. Somatic human cells contain two copies of nuclear DNA but they contain 
many more copies of mtDNA (from 1000 to 100 000, depending on the cell type). These 
are all identical in a healthy individual at birth (homoplasmy). Patients with mtDNA 
mutations often have a mixture of mutated and wild-type mtDNA (heteroplasmy): the 
percentage of mutated mtDNA can vary widely among different patients, from organ to 
organ, between cells, and even at the organellar level: a single mitochondrion can harbour 
both normal and mutant mtDNAs. 
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Threshold effect. A minimal number of mutant mtDNAs must be present before 
oxidative dysfunction occurs and clinical signs become apparent. Cells are able to tolerate 
high percentage levels of mutated mtDNA (typically 70–90%) before they developed a 
biochemical defect. The threshold for disease is lower in tissues that are highly dependent 
on oxidative metabolism (brain, heart, skeletal muscle, retina, renal tubules, and 
endocrine glands). 
Mitotic segregation. The random redistribution of organelles at the time of cell division 
can change the proportion of mutant mtDNAs received by daughter cells, leading to 
changes in the level of mutated mtDNA species in replicating tissues.  
Relaxed replication. mtDNA replication is independent of nDNA replication 
(“relaxed”): unlike nDNA which replicates only once during each cell cycle, mtDNA is 
continuously recycled, even in non-dividing tissues (e.g. skeletal muscle, brain). In a 
heteroplasmic cell, it is possible that mutated and wild-type mtDNA replicate at subtly 
different rates: this mechanism could lead to changes in the proportion of mutated 
mtDNA that have been described in patients with mtDNA disease, providing an 
explanation for the late onset and progression of some mtDNA disorders. 
It is of interest to note that other than the aforementioned 13 respiratory chain 
components, no other genes for structural proteins are found in human mtDNA. The 
mitochondrial genome is distinct from the nuclear genome in that it follows a strict 
maternal inheritance pattern. Within a cell, mtDNA replication is semi-autonomous and is 
not synchronized with the S phase of the cell cycle. However, the two genetic systems 
(nuclear and mitochondrial) appear to be closely coordinated by yet unknown 
mechanisms. Although the mitochondrion contains the necessary machinery to express its 
genome, many of its protein components are encoded by nuclear DNA. It is known that 
mtDNA is far more vulnerable to mutations than nuclear DNA due to its lack of histone 
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protection, limited repair capacity, and close proximity to the electron transport chain, 
which constantly generates superoxide radicals. Considering mtDNA lacks introns, most 
mutations occur in the coding sequences and are thus, likely to be of biological 
consequence. Because each cell contains many mitochondria with multiple copies of 
mtDNA, it is possible that wild-type and mutant mtDNA can co-exist in a state called 
heteroplasmy. Over time, the proportion of the mutant mtDNA within the cell can vary 
and may drift toward predominantly mutant or wild type to achieve homoplasmy. Thus, 
the biological impact of a given mutation may vary. This effect contributes to the various 
phenotypes observed amongst family members carrying the same pathogenic mtDNA 
mutation. 
 
3.1.6 Mitochondria dysfunctions 
Mitochondrial diseases can be caused by nDNA and mtDNA defects; some of them 
(e.g. myopathies with "ragged red fibres“) show accumulation of mitochondria similar to 
that seen in oncocytic tumours. 
There are six known essential alterations in cell physiology that collectively might 
dictate malignant transformation: self-sufficiency in growth signals, insensitivity to 
growth-inhibitory (antigrowth) signals, limitless replicative potential, sustained 
angiogenesis, tissue invasion and metastasis, and evasion of programmed cell death 
(apoptosis) [17]. In addition, there is a growing body of evidence suggesting that one of 
the early recognized peculiarities of tumour cells (i.e. their dependence on glycolysis for 
ATP generation) might be added to this list. In 1926, Otto Warburg found that cancer 
cells produce most of their ATP through glycolysis, even under aerobic conditions [18], 
and there was a correlation between glycolytic ATP production and aggressiveness of the 
tumour cells [19]. Warburg assumed that such ‘aerobic glycolysis’ was a universal 
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property of malignant cells and suggested that cancer is caused by impaired mitochondrial 
metabolism. He hypothesized that these cells could be eliminated through the inhibition 
of mitochondrial oxidative phosphorylation, which would reduce the activity of these 
organelles below a threshold level critical for cell survival, whereas mitochondria in 
normal cells would still be able to produce enough ATP. Independent of whether 
mitochondrial respiration is low or not, cancer cells do exhibit high rates of glycolysis 
aerobic or anaerobic. Mitochondria also produce reactive oxygen species (ROS), which 
are involved in the regulation of many physiological processes, but which might also be 
harmful to the cell if produced excessively. These functions are of crucial importance for 
tumour cell physiology, growth and survival. 
 
3.1.7 Alterations of energy-supplying pathways in tumours 
One of the main characteristics of cancer cells is their fast proliferation. As such, 
rapidly growing tumours easily become hypoxic owing to the inability of the local 
vasculature to supply an adequate amount of oxygen. Similar hypoxic conditions are 
usually lethal to non-malignant cells. However, tumour cells can successfully escape 
hypoxia-mediated death as a result of lowered expression or mutation of p53 [20]. Owing 
to the inability of mitochondria to provide enough ATP for cell survival under hypoxic 
conditions, tumour cells must upregulate the glycolytic pathway. This occurs by induction 
of hypoxia-inducible factor 1 (HIF-1) [21]. HIF-1 stimulates key steps of glycolysis, but 
regulates genes that control angiogenesis, cell survival and invasion. However, it should 
be mentioned that, in addition to hypoxia, other factors (e.g. hormones and growth 
factors) might cause stabilization of HIF-1 expression [22]. Stimulation of glycolysis can 
also occur by activation of phosphoinositide 3-kinase (PI3K) and its downstream target, 
Akt. Activation of Akt triggers increases in cell size, enhanced glycolytic activity and 
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metabolism, and cell survival [23], and is commonly observed in cancer cells [24]. When 
mitochondrial respiration in tumour cells is downregulated, accumulation of Krebs cycle 
substrates might serve as a signal for stimulation of glycolysis [25]. Defects in 
mitochondrial respiration cause enhanced levels of NADH, which can subsequently 
inactivate PTEN (phosphatase and tensin homologue) through a redox modification 
mechanism [26]. In addition to upregulating the glycolytic pathway, HIF-1 can initiate 
apoptosis by stabilization of p53 and/or induction of certain pro-apoptotic proteins. 
Therefore, during hypoxia, a complicated balance emerges between factors that stimulate 
or suppress apoptosis. 
 
3.1.8 ROS impairment 
Cancer cells are generally more active than normal cells in metabolic ROS generation 
and are constantly under oxidative stress. It is conceivable that certain mtDNA mutations 
may be caused by endogenous ROS in cancer cells. Alterations in mitochondrial 
functions could in turn cause further increases of ROS production, leading to more 
mutations and additional oxidative stress. Certain mtDNA mutations in cancer cells are 
likely to cause malfunctions of the respiratory chain and increase free radical generation. 
This biochemical change provides an unique opportunity to selectively kill this 
population of cancer cells by using agents that inhibit free radical elimination and cause 
further ROS accumulation, leading to lethal damage in the cancer cells [27]. Taken 
together, it is evident that mtDNA mutations are clinically relevant and have potential 
therapeutic implications. 
The hypoxic environment of proliferating tumour tissue facilitates ROS production. 
Therefore, under hypoxic conditions and, in particular, after normalization of oxygen 
supply, production of ROS in tumour cells can be enhanced to an extent that might induce 
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damage to vital cellular components, including mitochondrial DNA (mtDNA). This might 
trigger a vicious cycle (i.e. hypoxia, ROS production, mtDNA mutations, malfunction of 
the mitochondrial respiratory chain, further stimulation of ROS production etc.), thus 
impairing mitochondrial function and causing a shift to glycolytic ATP production. 
 
3.1.9 Upregulation of glycolysis in tumour 
The seemingly most obvious reason for a glycolytic shift in cancer cells is that 
molecular oxygen becomes unavailable in fast-proliferating cells, and thus the 
mitochondria cannot function properly in ATP production. Nevertheless, even after 
restoration of oxygen supply, tumour cells tend to utilize glucose and to keep 
mitochondrial activity suppressed. Apparently, ATP production is not the only reason 
why tumour cells favour this energetically unprofitable pathway. Furthermore, mounting 
evidence demonstrates that the amount of glucose entering cancer cells exceeds their 
bioenergetic demands. The high rate of glycolysis in most tumours not only compensates 
for mitochondrial dysfunction but also is required to support tumour cell proliferation. 
High intracellular glucose concentrations enable the cell to redirect the accumulated 
glycolytic end-product, pyruvate, toward lipid synthesis, which is necessary for 
membrane assembly. In addition, a shift to the glycolytic pathway with production of 
lactate creates an acidic environment that gives the cancer cells a competitive advantage 
for invasion, because the acidic environment is toxic for non-malignant cell populations 
[28]. Another important consequence of the glycolytic shift in tumour cells is their 
acquired resistance to apoptotic cell death. 
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3.1.10 Genetic and biochemical alterations in oncocytic tumours 
The best studied oncocytic tumours in terms of mtDNA are those of the thyroid. A 
large deletion encompassing 4,977 bp of mtDNA, known as the mtDNA common 
deletion (CD), is almost always detected and was proposed as a hallmark of oncocytic 
thyroid tumours [10, 29]. This deletion removes seven OXPHOS genes (ATPase6, 
ATPase8, COIII, ND3, ND4L, ND4 and ND5) and five tRNAs (glycine, arginine, 
histidine, serine and leucine), thus resulting in severe impairment of the OXPHOS 
system. The severe impairment of the OXPHOS system (as a consequence of the mtDNA 
CD) would engage and activate nuclear genes that control mitochondrial number, 
resulting in an increase in the mitochondrial mass [30]. The analysis of the prevalence of 
mtDNA mutations has shown that missense somatic mutations in complex I genes were 
more frequently detected in malignant tumours than in adenomas [10]. A significant 
association was also observed between D-loop somatic mutations and the occurrence of 
somatic mutations in other mtDNA genes [10]. The absence of complex I, together with 
an increase in the remaining complexes and citrate synthase, led to the conclusion that the 
mitochondrial proliferation might be a compensatory mechanism for a decreased 
OXPHOS activity [31]. The defective ATP production observed in some studies [32, 33] 
may explain the characteristic mitochondrial proliferation of oncocytic cells. 
Gasparre et al. [34] demonstrated that the oncocytic phenotype in thyroid carcinoma 
is associated with disruptive mutations in complex I subunits genes. They found a larger 
prevalence of nonsense and frameshift mutations caused by insertions or deletions in 
coding regions of mtDNA. Moreover, they found in one case of mitochondria-rich breast 
carcinoma, out of five analysed, a disruptive mutation. These mutations may arise as a 
second hit in tumour development and that the oncocytic phenotype in thyroid tumours 
may be strictly correlated with these mutations. 
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3.2 MATERIAL AND METHODS 
 
3.2.1 Case selection 
Group 1: 28 cases of surely oncocytic breast carcinomas were selected from 
Professor Eusebi consultations (8 cases) and from Bellaria Hospital files (20 cases) to 
identify the morphological and immunohistochemical characteristic of these tumours. 
Group 2: 84 consecutive breast carcinomas (years 1997-1998) were retrieved from 
the files of Bellaria Hospital (Bologna, Italy) and analyzed for checking the frequency of 
oncocytic tumours and for comparing these non-selected cases with the previous group. 
Group 3: A series of 18 putative oncocytic carcinomas of the breast was retrieved 
from the files of Bellaria Hospital, Bologna, Italy. A control group of 36 grade and ER-
matched invasive ductal carcinomas no-special-type (IDC-NSTs) were retrieved from the 
files of The Breakthrough Breast Cancer Research Centre (Institute of Cancer Research, 
London - UK). 
All cases were revised by two pathologists (GT and VE) and graded according to 
Elston & Ellis. Immunohistochemistry was assessed using the Ventana system. 
Representative sections from mt-rich BCs and IDC-NSTs were microdissected and DNA 
was extracted and subjected to aCGH using a 32K tiling path bacterial artificial 
chromosome array platform. aCGH results were subjected to unsupervised hierarchical 
clustering analysis and profiles were compared using a previously validated multi-Fisher's 
exact test with p values adjusted for multiple comparison by the false discovery rate. 
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3.2.2 Immunohistochemistry 
To perform a semiquantitative analysis of cytoplasmic content of mitochondria, anti-
mitochondria antibody (Ab-2, clone MTC02, LabVision Neomarker) has been optimized 
using as control a Warthin’s tumour. Optimal dilution was chosen using as reference the 
negativity of reaction in lymphocytes. Reaction was performer according to 
manufacturer’s protocol (Ultravision LP Detection System HRP Polymer – LabVision, 
Freemont, CA, U.S.A.). 
Cytoplasmic positivity was scored as follows (Fig.3.2): 
 
3+ (≥ 60%)  Strong Positivity (Oncocytic Cells) 
2+ (< 60% / >30%)  Moderate Positivity (Mitochondrial Rich Cells) 
Neg/1+  Weak positivity or absent positivity 
 
3+ 2+
 
Figure 3.2: Staining of a Warthin's tumour using Ab anti-mitochondria. 3+: strong 
positivity, corresponding to oncocytic cells. 2+: moderate positivity, corresponding to 
mitochondrial rich cells. 
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Tumours were reclassified according to intensity of positivity and to percentage of 
positive neoplastic cells (Figures 3.3, 3.4, 3.5). 
• Oncocytic Carcinoma (OC): 3+ ≥ 70% of the cells 
 
Figure 3.3  
 
• Mitochondria-rich carcinoma (mt-rich): 2+ >50% or 3+ <70% and >30% 
 
Figure 3.4 
 
• Carcinoma not enriched in mitochondria (non mt-rich): 1+/Neg or 2+ ≤50% or 3+ 
≤30% 
 
Figure 3.5 
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Immunohistochemistry was assessed using the Ventana system (Ventana-Benchmark, 
Tucson, Arizona, U.S.A.) for all the antibodies analysed (Tab. 3.1) but not for anti-
mitochondria. Positivity for ER and PR has been evaluated according to St.Gallen criteria 
2005 (>10%) and 2009 (>1%). 
 
ANTIBODIES Clone – Ventana Prediluted 
Antigen Retrieval/ Detection 
System 
ER SP1 CC1^# 
PR 1E2 CC1^# 
AR AR441 CC1^# 
NEU CB11 CC1^* 
GCDFP-15 23A3 CC1^* 
Chromogranin LK2H10 CC1^* 
EMA E29 CC1^* 
CK7 OV-TL 12/30 
Protease enzimatic 
digestion* 
CK14 LL002 CC1^* 
CD68 PGM1 CC1^* 
Table 3.1: Antibodies used for tumours characterization. ER: Oestrogen Receptor; PR: Progestin 
Receptor; AR: Androgen Receptor; HER2/Neu: Human Epidermal Growth Factor Receptor 2; GCDFP-15: 
Gross Cystic Disease Fluid Protein; EMA: Epithelial Membrane Antigen; CK: Cytokeratin; CD: 
Differentiation Cluster. ^ Ventana-Benchmark, Tucson, Arizona, U.S.A. #Detected by “Universal alkaline 
phosphatase red detection system” (Ventana-Benchmark); *Detected by “Ultraview universal DAB 
detection system (Ventana-Benchmark) 
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3.2.3 Electron Microscopy 
For electron microscopy, small blocks were microdissected from paraffin-embedded 
samples in 6 cases where mitochondria–positive cells were numerous. These small blocks 
were dewaxed by overnight immersion in xylol and rehydrated to phosphate buffer, 
through a graded series of alcohol dilutions. Biopsies were then refixed in buffered 
glutaraldehyde, postfixed in OsO4, dehydrated in alcohol, and embedded in Epon 812 
(Fort Washington, Pa). Thick sections stained with toluidine blue were used to select 
areas to examine. Thin sections were stained with uranyl acetate and Reynold’s lead 
citrate, and observed in a Philips CM 10 TEM (Philips, Eindhoven, Netherlands). 
 
3.2.4 Follow-up 
72 out of 81 cases of invasive breast carcinoma belonging to group 2 (years 1997-
1998, from 6 to 144 months of FU, mean 96,69) were evaluated for follow-up analysis: 5 
were lost to follow-up and 4 excluded because recurrences. 
Overall free survival was calculated by GraphPad Prism© tool. Kaplan-Maier curves were 
compared using Wilcoxon and Mantel-Cox test. 
 
3.2.5 Microdissection and DNA extraction 
All cases were microdissected to ensure >90% of purity of cancer cells. 
Microdissection was performed with a sterile needle under a stereomicroscope (Olympus 
SZ61, Japan) from five consecutive 8μm-thick sections stained with nuclear fast red. 
DNA was extracted in 200 μl digestion buffer [100 mM NaCl, 10 mM Tris–HCl (pH 8.0), 
25 mM EDTA (pH 8.0), 0.5% SDS, 0.5 mg/ml Proteinase K (Invitrogen Life 
Technologies)] and was purified by phenol/ chloroform extraction in Phase Lock Gel 
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Lighttubes (Eppendorf, Hamburg, Germany). The purified DNA samples were ethanol-
precipitated and the DNA resuspended in TE buffer (pH 7.5). 
DNA concentration was measured with PicoGreen® assay as manufacturer’s 
instructions (Invitrogen, Paisley, UK). DNA quality was assessed using four primer sets 
in a multiplex PCR [35]. 
 
3.2.6 Microarray comparative genomic hybridisation analysis (aCGH) 
The 32K BAC re-array collection (CHORI) tiling path aCGH platform used for this study 
and DNA labelling and array hybridisation were previously described (see “Genetic 
Eterogenicity in Metaplastic Breast Carcinoma” chapter). 
Data analysis. Cases with >10% of clones missing and clones where data were not 
available in ≥10% of cases were excluded. Log2 ratios were normalised for spatial and 
intensity dependent biases using a two-dimensional loess regression followed by a BAC-
dependent bias correction as previously described. This left a final data set of 30 820 
clones with unambiguous mapping information according to the March 2006 build (hg18) 
of the human genome (http://www.ensembl.org). Data were smoothed using a local 
polynomial adaptive weights smoothing (aws) procedure for regression problems with 
additive errors. A categorical analysis was applied to the BACs after classifying them as 
representing gain, loss, or no-change according to their smoothed Log2 ratio values. A 
categorical analysis was applied to each clone on the array after classification as gain, 
loss, or no-change according to their smoothed log2 ratio values. Smoothed log2 ratio 
values less than −0 .12 were categorized as losses; those between 0.12 and 0.40 as gains 
(corresponding to approximately 3-5 copies of the locus); and those in between as 
unchanged. Amplifications were defined as smoothed log2 ratio values greater than 0.40 
(corresponding to more than 5 copies). Data processing and analysis were carried out in R 
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2.0.1 (http://www.r-project.org/) and BioConductor 1.5 (http://www.bioconductor.org/), 
making extensive use of modified versions of the packages aCGH, marray, and aws in 
particular. Copy number changes were categorized as gains, losses or amplifications 
according to the aforementioned thresholds for each clone before using Fisher’s exact test 
(with adjustment for multiple testing). 
Data were smoothed using the circular binary segmentation (cbs) algorithm [36, 37]. 
A categorical analysis was applied to the BACs after classifying them as representing 
gain, loss or no-change according to their smoothed Log2 ratio values [38, 39]. Threshold 
values were chosen to correspond to three standard deviations of the normal ratios 
obtained from the filtered clones mapping to chromosomes 1-22, assessed in multiple 
hybridisations between DNA extracted from a pool of male and female blood donors as 
previously described [40] (Log2 ratio of ±0.12). Low level gain was defined as a 
smoothed Log2 ratio of between 0.12 and 0.40, corresponding to approximately 3–5 
copies of the locus, whilst gene amplification was defined as having a Log2 ratio >0.40, 
corresponding to more than 5 copies. 
 
3.2.7 Mitochondrial DNA sequencing 
Mitochondrial DNA was sequenced using mitoALL™ Resequencing Amplicon, 
RSS000056015_01, for resequencing the entire mitochondrial genome with 46 RSAs 
mitoSEQr™ Resequencing Amplicons for mtDNA [Applied Biosystems]. The mitoSEQr 
system is designed for detecting sequence variants in human mtDNA. Pre-designed PCR 
primers tailed with M13 sequences generate either 9 resequencing amplicons (RSAs) for 
the mtDNA control region or 46 RSAs for the entire mitochondrial genome, as indicated. 
The PCR primers are provided ready to use and anneal at the same temperature. 
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Alteration of mtDNA in mt-rich BCs mtDNA was analyzed in 12 mt-rich BCs: in 6 cases 
at least 2000 bp were sequenced (>15% of 16,569-bp genome) (Fig. 3.6); results checked 
with mitomap (www.mitomap.org) and PolyPhen (Polymorphism Phenotyping) 
(http://genetics.bwh.harvard.edu/pph/) MitoRes v1.4 
http://genetics.bwh.harvard.edu/pph/. 
PolyPhen (=Polymorphism Phenotyping) is an automatic tool for prediction of possible 
impact of an amino acid substitution on the structure and function of a human protein. 
This prediction is based on straightforward empirical rules which are applied to the 
sequence, phylogenetic and structural information characterizing the substitution.  
 
 
 
 
Figure 3.6: Scheme of mt-DNA covered by sequencing in 6 cases analysed 
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3.2.8 Nuclear genes codifying for mitochondrial protein 
71 (out of about 800) nuclear genes for mitochondrial functions (chosen because 
implicated in mitochondrial syndrome or for their functions [41, 42]) were analysed using 
Fisher’s exact test for comparing mt-rich/OC carcinomas (n=17) with IDC-NSTs samples 
(n=34) (Tab. 3.2). 
 
ABCB7 MNF1 SCO2 
ANT1 MFN2 SDHA 
ANT2 MIL1 SDHB 
ATPAF2 MRPS15 SDHC 
BAD MTIF2 SDHD 
BCLB NDUFA2 SOD1 
BCS1L NDUFB9 SOD2 
C10orf2 NDUFS1 SPG7 
CHCHD3 NDUFS2 SSBP1 
COX10 NDUFS4 SURF1 
COX15 NDUFS7 TAZ 
CYB5B NDUFS8 TFBP1 
DDX28 NDUFV1 TFBP2 
DGUOK NDUFV2 TIMM44 
DNC OPA1 TIMM8A 
DRP1 PDHA1 TK2 
ETHE1 PDP1 TOP1MT 
FH PDP2 TYMP 
FXN POLG1 UNG 
GFM1 POLG2 UQCRB 
GOT2 POLRMT VDAC1 
GRIM19 PTRF VDAC2 
IMMT RMRP VDAC3 
LRPPRC SCO1  
Table 3.2: Analysed nuclear genes codifying for mitochondrial protein  
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3.3. RESULTS 
 
3.3.1 Group 1 (selected OC). 
All the 28 patients were female, aged from 26 to 87 years (mean 65,3 y). The cases 
counted 25 IDC NOS, 2 CDI “special types” and 1 ILC. 57% (16/28) were grade III, 36% 
(10/28) grade II and 7% (2/28) grade I (Tab. 3.3). All the cases were studied by IHC 
(Tab. 3.4). According to positivity to anti-mitochondria antibody, 17 cases have been 
reclassified as “oncocytic”, 10 as “mitochondria rich” and one (Mit17) as “negative” and 
presented an apocrine differentiation. 
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CASE AGE DIAGNOSIS GRADE STAGE MIT. ER% PR% Neu APO CHR AR CK7 CK14 EMA CD68 
Mit1 87 IDC G3 pT2, N0, M1 
2+ 
(80%) 65 60 - - - - - - + - 
Mit2 70 IDC G2 pT1a, N0, M0 
2+ 
(70%) 90 90 - - - - + - + - 
Mit3* 78 IDC G3 pT2, N1a 
2+ 
(70%) 90 40 2+ - - + - - + - 
Mit4* 68 IDC G3 pT2, N1a 
3+ 
(90%) - - 3+ + - + + - + - 
Mit5* 83 IDC G2 pT1c, N0 
2+ 
(90%) 80 20 2+ - - - - - + - 
Mit6* 51 IDC G3 pT2, N2a 
2+ 
(70%) 20 - 2+ - - - + - + - 
Mit7* 45 IDC G3 pT1c, N0 
3+ 
(90%) 80 50 1+ - - + - - + - 
Mit8* 58 IDC G2 pT1c, N1a 
3+ 
(90%) 90 50 3+ - - - - - + - 
Mit9* 66 IDC G3 pT1c, Ns0 
3+ 
(90%) - - 2+ - - - + - + - 
Mit10* 49 IDC G3 pT1c, N1a 
2+ 
(70%) 80 70 2+ - - - + - Foc - 
Mit11* 50 IDC G3 pT1c, Ns1a 
2+ 
(70%) - - 3+ Foc - + + - + - 
Mit12* 79 IDC G3 pT3, N0 3+ (90%) 10 - 3+ + - + + - + - 
Mit13* 26 IDC G3 pT2, N2 3+ (80%) 15 - 3+ Foc - - + - + - 
Mit14* 71 ILC G3 pT3, N3 2+ (80%) 80 - - - - - + - + - 
Mit15* 76 IDC G3 pT2, N0 3+ (80%) 90 - 3+ - - - - - - - 
Mit16* 61 IDC G2 pT1b, Ns0 
3+ 
(90%) 95 95 - Foc - + + - + - 
Mit17* 72 IDC G2 pT1c, N0 - 95 30 - + - + Foc - + - 
Mit18* 76 IDC G2 pT2, N0 3+ (90%) 85 45 1+ Foc - - + - + - 
Mit19* 76 IDC G3 pT2, N3 3+ (90%) 95 45 2+ - + + + - + - 
Mit20* 65 IDC G3 pT1c, Ns0 
2+ 
(70%) - - - - - - + Foc + - 
Mit21 52 IDC “simil Hashimoto” G2 
pT1b, 
N1 
3+ 
(90%) 90 40 - - - + - - + - 
Mit22 41 IDC G2 pT2, N0 3+ (90%) 95 90 - - - + + - + - 
Mit23 58 IDC BTRPTC G1 pT1b 
3+ 
(90%) 50 - - - - - + - Foc - 
Mit24 76 IDC G2 pT2, N0 2+ (60%) 95 15 - - - - Foc - - - 
Mit25 85 IDC G2 n.d. 3+ (90%) 95 95 - - - - + - + - 
Mit26 70 IDC G1 pT2 3+ (80%) 90 70 - - + - - - + - 
Mit27 55 IDC G3 pT4 3+ (70%) 90 80 - - - - + - + - 
Mit28 66 IDC G3 pT2, N1 3+ (80%) 90 - 3+ - - - - - + - 
Table 3.3: Results of anatomo-clinical results of group 1 carcinomas. IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular 
Carcinoma; BTRPTC: Breast Tumour Resembling Papillary Thyroid Carcinoma (tall cell variant); Foc: Focal, <20%; *: cases 
analyzed by aCGH. In red: oncocytic carcinomas. N.a.: not available; Neu: HER2/Neu score according to guidelines of ASCO CAP 
2007 [43]. 
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AB Positive 
Cases 
% 
APO 
(focal) 
3/28 
(4/28) 
10,7 
(14,3) 
Chromogranin 2/28 7,1 
ER (>10%) 
    (>1%) 
22/28 
(23/28) 
78,6 
(82,1) 
PR (>10%) 
    (>1%) 
17/28 
(17/28) 
60,7 
(60,7) 
HER2/Neu 7/28 25 
AR 10/28 35,7 
EMA 
(focal) 
24/28 
(2/28) 
85,7 
(7,1) 
CK7 
(focal) 
17/28 
(2/28) 
60,7 
(7,1) 
CK14 
(focal) 
0/28 
(1/28) 
/ 
(3,6) 
CD68 0/28 / 
Table 3.4: Pannell of immunohistochemistry results of 28 cases belonging to group 1. 
 
 
3.3.2 Group 2 (consecutive cases 1997-1998) 
81 consecutive breast carcinomas (years 1997-1998), 78 women and 3 men, 
aged from 32 to 96 years (mean 66.1 y). Series included 58 IDC, 11 ILC, 2 mixed 
(ductal/lobular) and 10 “special types”: grade III were 31/81 (38.3%), grade II were 
42/81 (51.8%) and grade I 8/81 (9.9%). 
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All cases were analyzed by anti-mitochondria antibody, Out of these 81 cases, 
47 (58%) were reclassified as “not enriched in mitochondria”, 18 (22.2%) as “mt-
rich” and 16 (19.8%) as “OC” (Tab. 3.5). 
Frequency of oncocytic carcinoma was so estimated as 19.8%. 
 
 SEX AGE (y) 
FU 
(m) DG G STAGE IHC MIT RECLASS 
1 F 66 26 A IDC Mix. Muc. G2 pT2, N0, 2+ (80%) Mt-Rich 
2 F 47 144 A ILC G2 pT2, N1a neg Not Mt-Rich 
3 F 51 144 A 
IDC Pure 
Muc. G1 pT2 1+ (90%) Not Mt-Rich 
4 F 85 56 D IDC G3 pT3, N1a 1+ (70%) Not Mt-Rich 
5 F 60 26 D IDC G3 pT2, N0, 3+ (80%) OC 
6 F 76 143 A IDC G2 pT2, N0 neg Not Mt-Rich 
7 F 77 143 A IDC G1 pT1c, N0, 2+ (70%) Mt-Rich 
8 F 66 119 A IDC G3 pT1b, N0 neg Not Mt-Rich 
9 F 66 142 A IDC G2 pT2, N1, 1+ (60%) Not Mt-Rich 
10 F 74 29 D IDC G3 pT1c, N0 3+ (70%) OC 
11 F 77 26 D IDC G2 pT1b 2+ (60%) Mt-Rich 
12 F 83 12 Dx IDC G1 pT1c, N0 neg Not Mt-Rich 
13 F 56 82 D IDC Apo. G3 Rec 2+ (80%) Mt-Rich 
14 F 65 52 D ILC G2 pT1c, N3a 2+ (60%) Mt-Rich 
15 F 84 101 Dx IDC G2 pT1c, N0, 1+ (70%) Not Mt-Rich 
16 F 32 140 A IDC G3 pT1c, N1, 1+ (30%) Not Mt-Rich 
17 F 69 140 A ILC G2 pT1c, N0 neg Not Mt-Rich 
18 F 58 139 A IDC G3 pT2, N0 3+ (70%) OC 
19 F 68 n.d. IDC G3 pT2, N1 3+ (80%) OC 
20 F 76 34 D IDC Pure Muc. G1 pT2 1+ (30%) Not Mt-Rich 
21 F 67 139 A 
IDC Pure 
Muc. G1 pT2, N0 neg Not Mt-Rich 
22 F 45 65 D IDC G3 pT2, N3a, 1+ (25%) Not Mt-Rich 
23 F 57 138 A ILC G2 pT2, N2a 2+ (60%) Mt-Rich 
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 SEX AGE (y) 
FU 
(m) DG G STAGE IHC MIT RECLASS 
24 F 55 122 D ILC G2 pT4, N3a 1+ (50%) Not Mt-Rich 
25 F 79 25 Dx 
IDC Pure 
Muc. G1 pT1c 3+ (70%) OC 
26 M 68 137 A IDC G2 pT4, N0 3+ (80%) OC 
27 F 76 136 A IDC G2 pT1a, N1 neg Not Mt-Rich 
28 F 86 41 D ILC+IDC G2 pT4, N0 1+ (10%) Not Mt-Rich 
29 F 84 29 D IDC Apo. G3 pT4, N3a, M1 3+ (70%) OC 
30 F 58 136 A IDC G3 pT2, N1, 1+ (80%) Not Mt-Rich 
31 F 96 6 Dx IDC G2 pT2 1+ (10%) Not Mt-Rich 
32 F 52 70 Dx IDC G2 pT4, N0 1+ (70%) Not Mt-Rich 
33 M 76 96 Dx IDC G1 
pT1b, N1, 
M1 1+ (40%) Not Mt-Rich 
34 F 75 134 A IDC G2 pT1c, N0 1+ (20%) Not Mt-Rich 
35 F 77 134 A ILC G3 Rec 1+ (15%) Not Mt-Rich 
36 F 49 134 A IDC G2 pT2, N0 1+ (20%) Not Mt-Rich 
37 F 65 134 A IDC G2 pT1c, N2 neg 
Not Mt-Rich 
38 F 57 15 D IDC G3 pT2, N1, M1 3+ (70%) OC 
39 F 70 55 A IDC G3 pT2, N2, 2+ (70%) Mt-Rich 
40 F 64 15 D ILC pleomorfic G3 Rec 2+ (50%) Mt-Rich 
41 F 40 133 A IDC G3 pT3, N1, 2+ (60%) Mt-Rich 
42 F 54 50 D IDC G3 pT2, N2 1+ (10%) Not Mt-Rich 
43 F 63 133 A IDC G3 pT1c, N1, 1+ (60%) Not Mt-Rich 
44 F 67 116 Dx IDC G2 pT1c, N0 1+ (25%) Not Mt-Rich 
45 M 66 29 D IDC G2 pT4, N1 1+ (50%) Not Mt-Rich 
46 F 67 88 D IDC G2 pT2, N1 3+ (90%) OC 
47 F 68 131 A IDC G3 pT2, N0 3+ (90%) OC 
48 F 49 130 A IDC G3 pT2, N0 3+ (70%) OC 
49 F 81 69 D IDC  G1 pT1a, N0 1+ (10%) Not Mt-Rich 
50 F 68 129 A IDC G3 pT1c, N0 2+ (60%) Mt-Rich C
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 SEX AGE (y) 
FU 
(m) DG G STAGE IHC MIT RECLASS 
51 F 58 128 A ILC  G2 pT2, N2 1+ (30%) Not Mt-rich 
52 F 52 128 A IDC G3 pT1c, N0 2+ (80%) Mt-Rich 
53 F 60 127 A IDC G3 pT4, N2 neg Not Mt-Rich 
54 F 60 127 A IDC G2 pT2, N1, 1+ (10%) Not Mt-Rich 
55 F 74 77 D IDC G2 pT4, N0 3+ (70%) OC 
56 F 63 127 A IDC G2 pT1c, N2 2+ (60%) Mt-Rich 
57 F 71 100 D IDC G2 pT4, N1 1+ (50%) Not Mt-Rich 
58 F 70 127 A ILC G2 pT1c, N0 1+ (30%) Not Mt-Rich 
59 F 74 10 D ILC G2 pT2, N3a 2+ (60%) Mt-Rich 
60 F 85 n.d. IDC Mix Muc G2 pT3 3+ (90%) OC 
61 F 50 21 A IDC. G2 pT2, N1, 2+ (60%) Mt-Rich 
62 F 50 38 D AMC G3 pT2, N1 1+ (40%) Not Mt-Rich 
63 F 94 126 A IDC G2 pT4 3+ (90%) OC 
64 F 66 n.d. IDC G3 pT1c, N2 2+ (60%) Mt-Rich 
65 F 75 126 A ILC G2 pT2, N0, 1+ (30%) Not Mt-Rich 
66 F 64 38 D IDC G3 pT4, N3a 2+ (60%) Mt-Rich 
67 F 59 37 D IDC G3 Rec 3+ (80%) OC 
68 F 40 125 A IDC G2 pT2, N1b 1+ (30%) Not Mt-Rich 
69 F 81 124 A IDC+ILC G2 pT1c, N1 neg Not Mt-Rich 
70 F 80 35 D IDC G2 pT1c, N0 neg Not Mt-Rich 
71 F 84 51 Dx IDC G2 pT2 1+ (50%) Not Mt-Rich 
72 F 60 7 D IDC G3 Rec, M1 2+ (60%) Mt-Rich 
73 F 50 43 A IDC G3 pT1c, N1, 1+ (30%) Not Mt-Rich 
74 F 65 64 D IDC G3 pT1a, N0, 1+ (60%) Not Mt-Rich 
75 F 69 122 A IDC G2 pT1b, N0 2+ (50%) Mt-Rich 
76 F 70 122 A IDC G3 pT2, N3a, 3+ (90%) OC 
77 F 49 122 A ILC G2 pT1c, N1 1+ (30%) Not Mt-Rich 
78 F 73 113 Dx IPC G2 pT4, N0 1+ (20%) Not Mt-Rich 
79 F 68 121 A IDC G2 pT1b, N0, neg Not Mt-Rich 
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 SEX AGE (y) 
FU 
(m) DG G STAGE IHC MIT RECLASS 
80 F 56 n.d. IDC G2 pT1c, N0 1+ (10%) Not Mt-Rich 
81 F 69 132 A IDC G2 pT1c, N1, 1+ (10%) Not Mt-Rich 
Table 3.5: Reclassification of invasive breast carcinomas from 1997 to 1998 (Group 2). Has been 
reported the values of positivity for tumours reclassification. IDC: Invasive Ductal Carcinoma; ILC: 
Invasive Lobular Carcinoma; AMC: Atypical Medullary Carcinoma; IPC: Invasive Papillary Carcinoma; 
Reclass: reclassification; Mix Muc Mixed Mucinous; FU: Follow-up; A: alive; D: death of breast 
carcinoma; Dx: death for other causes; n.a.: not available. 
 
 
3.3.3 Oncocytic carcinomas 
To determinate the anatomo-clinical and immunohistochemical characteristic of 
oncocytic carcinoma we put together the cases reclassified as OC from the group 1 
and group 2. In this way we obtained a total of 33 oncocytic carcinomas (17 from 
group 1 and 16 from group 2). 
Of these 33 samples, 32 were female (96.97%) and one case was a male 
(3.03%), age ranged from 26 and 94 years (mean 65.8 y). All 33 cases were IDC: 
28/33 (84.8%) were NOS and 5 (15.2%) “special-types” (Tab. 3.6). 
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Case Age FU Diagnosis G Stage Mit APO CHR ER% PR% Neu AR EMA CK14 CK7 CD68 
5 60 26 D IDC G3 
pT2, 
N0 
3+ 
(80%) - - 10 5 - - + - + - 
10 74 29 D IDC G3 
pT1c, 
N0 
3+ 
(70%) + - 90 60 2+ - + - + - 
18 58 139 V IDC G3 
pT2, 
N0 
3+ 
(70%) - - 90 5 - - + - + - 
25 79 25 Dx 
IDC pure 
Muc G1 pT1c 
3+ 
(70%) - + 85 85 -  + - + - 
26 M68 137 V IDC G2 
pT4, 
N0 
3+ 
(80%) - - 70 20 - - Foc - + - 
29 84 29 D IDC Apo. G3 
pT4, 
N3a 
3+ 
(70%) + - 2 2 - + + - + - 
38 57 15 D IDC G3 
pT2, 
N1 
3+ 
(70%) Foc - - - 3+ - + - + - 
46 67 88 D IDC G2 
pT2, 
N1 
3+ 
(90%) + - 90 90 - - + - + - 
47 68 131 V IDC G3 
pT2, 
N0 
3+ 
(90%) - - - - 3+ - + - + - 
48 49 130 V IDC G3 
pT2, 
N0 
3+ 
(70%) Foc - 70 20 - - + - + - 
55 74 77 D IDC G2 
pT4, 
N0 
3+ 
(70%) - - 90 85 - - + - + - 
63 94 126 V IDC G2 pT4 
3+ 
(90%) - - - - - - + - + - 
76 70 122 V IDC G3 
pT2, 
N3a 
3+ 
(90%) - - 50 20 - - + - Foc - 
19 68 Nd IDC G3 pT2, N1 
3+ 
(80%) - - - - - - + + + - 
60 85 Nd IDC Mix Muc G2 pT3 
3+ 
(90%) - - 90 70 - - + - Foc - 
67 59 Nd IDC G3 Rec 3+ (80%) Foc - 80 5 - - + - + - 
Mit4 68 Nd IDC G3 pT2, N1a 
90 
(3+) + - - - 3+ + + - + - 
Mit7 45 Nd IDC G3 pT1c, N0 
90 
(3+) - - 80 50 1+ + + - - - 
Mit8 58 Nd IDC G2 pT1c, N1a 
90 
(3+) - - 90 50 3+ - + - - - 
Mit9 66 Nd IDC G3 pT1c, Ns0 
90 
(3+) - - - - 2+ - + - + - 
Mit12 79 Nd IDC G3 pT3, N0 
95 
(3+) + - 10 - 3+ + + - + - 
Mit13 26 Nd IDC G3 pT2, N2 
90 
(3+) + - 15 10 3+ - + - + - 
Mit15 77 Nd IDC G3 pT2, N0 
80 
(3+) - - 85 10 3+ - - - - - 
Mit16 61 Nd IDC G2 pT1b, Ns0 
90 
(3+) - - 95 95 - + + - + - 
Mit18 76 Nd IDC G2 pT2, N0 
90 
(3+) - - 85 45 1+ - + - + - 
Mit19 76 Nd IDC G3 pT2, N3 
90 
(3+) - + 95 45 2+ + + - + - 
Mit21 52 Nd IDC like Hashimoto G2 
pT, 
N1 
90 
(3+) - - 90 40 - + + - - - 
Mit22 41 Nd IDC G2 pT2, N0 
90 
(3+) - - 95 90 - + + - + - 
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Case Age FU Diagnose G Stage Mit APO CHR ER% PR% Neu AR EMA CK14 CK7 CD68 
Mit23 58 Nd IDC BTRPTC G1 pT1b 
90 
(3+) - - 50 - - - 
+ 
(FOC) - + - 
Mit25 85 Nd IDC G2 nd 90 (3+) - - 95 95 - - + - + - 
Mit26 70 Nd IDC G1 pT2 80 (3+) - + 90 70 - - + - - - 
Mit27 55 Nd IDC G3 pT4 70 (3+) 
- 
(FOC) - 80 80 - - + - + - 
Mit28 66 Nd IDC G3 pT2, N1 
80 
(3+) - - 90 5 3+ - + - - - 
Table 3.6: Anatomo-clinical and immunohistochemical characteristic of 33 OC. IDC: Invasive Ductal Carcinoma; 
BTRPTC: Breast Tumour Resembling Papillary Thyroid Carcinoma (tall cell variant); Mix Muc: Mixed Mucinous; Rec: 
recurrent; Foc: Focal, <20%; A: alive; D: death for pathology; Dx: death for other cause; N.a.: not available; Neu: HER2 
score according to ASCO CAP 2007 guidelines [43]
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3.3.4 Anatomo-clinical features 
The cases were especially of grade II and III, with dimension ranged from 2 cm e 5 
cm (pT2), with or without lymphnodal metastases (Tab. 3.7). 
 
Grade  Cases(%) 
I  3/33 (9%) 
II  11 /33 (33%) 
III  19/33 (58%) 
T  
1  7/30 (23%) 
2  16/30 (53%) 
3  2/30 (7%) 
4  5/30 (17%) 
N  
0  14/25 (56%) 
1 7/25 (28%) 
2  1/25 (4%) 
3  3/25 (12%) 
Table 3.7: Grade, pT and N of oncocytic carcinomas 
 
Morphologically appeared with solid nests, cellular shape from round to polygonal, 
eosinophilic cytoplasm. Nuclei were especially pleomorfic and sometimes could be 
associated a lymphoid stroma (Tab. 3.8; Figs. 3.7-3.10). 
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Features Description  Number of cases 
(%) 
Patterns of Growth 
Solid Nests 23 (70%) 
Glandular 2 (6%) 
Cribriform  15 (24%) 
Plexiform  2 (6%) 
Papillary 1 (3%) 
Margins 
Infiltrative 16 (48%) 
Pushing 17 (52%) 
Cellular Shape 
Round to Polygonal 32 (97%) 
Columnar to Cuboidal  1 (3%) 
Cytoplasm 
Eosinophylic  30 (91%) 
Clear 3 (9%) 
Nuclei 
Monomorphic   8 (24%) 
Pleomorphic 25 (76%) 
Nucleoli 
Prominent 23 (70%) 
Incospicous 10 (30%) 
Lymphoid Stroma 
Present 19 (57%) 
Absent 14 (43%) 
Table 3.8: Main morphological characteristics of oncocytic carcinomas 
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Figure 3.7: H&E of a GI oncocytic carcinoma 
 
 
 
 
Figure 3.8: H&E of a GII oncocytic carcinoma 
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Figure 3.9: E/E of a GII oncocytic carcinoma lymphnodal. Inside square: IHC with anti-mitochondria 
antibody 
 
 
 
 
Figure 3.10: E H&E of a GIII oncocytic carcinoma. 
Inside square: mitosis detail. 
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3.3.5 Immunohistochemical features  
At immunohistochemical level, most of the cases showed a positivity for ER, EMA 
and CK7. Sometimes could be associated an endocrine or apocrine differentiation (Tab. 
3.9). 
 
Ab Cases + % 
APO 
(focal) 
6/33 
(6/33) 
18,1 
(18,1) 
Chromogranin 3/33 9,1 
ER (>10%) 
   (>1%) 
24/33 
(27/33) 
72,7 
(81,8) 
PR (>10%) 
   (>1%) 
18/33 
(25/33) 
54,5 
(75,6) 
HER2/Neu 
(3+) 8/33 24,2 
AR 8/33 24,2 
EMA 
(focal) 
30/33 
(2/33) 
90,9 
(6,1) 
CK14 1/33 3 
CK7 
(focal) 
25/33 
(2/33) 
75,8 
(6,1) 
CD68 0/33 / 
Table 3.9: Immunohistochemical pattern of oncocytic carcinomas. 
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3.3.6 Electron Microscopy 
At electron microscopy, the six OC samples showed similar ultrastructural features. 
Numerous mitochondria were present scattered throughout the cytoplasm, from round to 
ovoid, sometimes swollen with flattened cristae. No secretory granules, vesicles or 
lysosome have been observed (Fig. 3.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Electronic Microscopy of an OC. The 
mitochondria are swollen with flattened cristae. Inside 
square: particular of mitochondria. 
 
3.3.7 Follow-up 
No statistically significant differences in prognosis were observed in survival 
analysis (Wilcoxon and Mantel-Cox test, p<0.05), even if oncocytic carcinomas seemed 
to show a tendency towards a worst prognosis in comparison to IDC not enriched in 
mitochondria. This pattern was observed considering OC associated, or not, with 
mitochondria-rich carcinomas (Fig. 3.12) and reached a statistical significativity (p<0.05) 
comparing OC/mt-rich (grade II) with not-mtRich (grade II) (Fig. 3.14A) and mt-rich 
(grade II) with not-mtRich (grade II) (Fig. 3.16A). No differences were reported 
comparing grades III (Figs. 3.12-3.16) or different pT (pT2, pT4) (Figs. 3.12-3.16). 
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ori oncocitici Figure 3.12: Kaplan-Meier. Analysis of overall survival for OC, mt-rich and not-mtRich. N.S. Wilcoxon and Mantel-Cox 
tests. 
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Figure 3.13: Kaplan-Meier. Analysis of overall survival in OC in comparison to not-mtRich. N.S. Wilcoxon and Mantel-Cox 
Test. 
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Figure 3.14: Kaplan-Meier. Analysis of overall survival of OC/mt-rich in comparison to not-mtRich. N.S. Wilcoxon and 
Mantel-Cox Test. *: statistically different at Wilcoxon Test (p<0.05). 
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Figure 3.15: Kaplan-Meier. Analysis of overall survival of OC in comparison to mtRich. N.S. Wilcoxon and Mantel-Cox Test. 
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Figure 3.16: Kaplan-Meier. Analysis of overall survival of mt-rich in comparison to not-mtRich. N.S. Wilcoxon and 
Mantel-Cox Tests. *: statistically different at Wilcoxon Test (p<0.05). 
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3.3.8 Molecular Analysis (aCGH) 
Out of 18 cases belonging to group 1 and analyzed by aCGH BAC, 7 cases were 
classified as “mt-rich”, 10 as “OC” and 1 as “not mt-rich” (Tab. 4.1). 
Unsupervised cluster analysis revealed that OC and mt-rich carcinomas were 
different at molecular level if compared to IDC NAS. It is possible to observe two 
different group (Fig. 3.17): one with a prevalence of IDC NAS and another one with 
abundance of OC/mt-rich carcinomas. 13 out of 18 selected samples grouped in the same 
cluster (considering data smoothed or thresholded), while 5 fell out: 1 control (mit17, 
negative at IHC, with an apocrine differentiation); 3 mt-rich (mit5, mit6, mit20); 1 OC 
(mit4). 
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Figure 3.17: Hierarchical clustering analysis based on the adaptive weight smoothed data (A) or 
thresholded data (B, gains, losses and amplifications). Although cluster “red” is significantly enriched 
for mt-rich breast cancers (cluster A vs other clusters, Fisher’s exact test p values <0.005 and 0.001 for A 
and B, respectively), these tumours are still heterogeneous at the genetic level. 
 
Data were smoothed using the circular binary segmentation (cbs) algorithm. A 
categorical analysis was applied to the BACs after classifying them as representing gain, 
loss or no-change according to their smoothed Log2 ratio values (Fig. 3.18). 
 
A 
B 
Mt-Rich Cluster 
Mt-Rich Cluster 
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Figure 3.18: Genome plot of mt-rich BCs. Log2 ratios are plotted on the Y axis against each clone 
according to genomic location on the X axis. Log2 ratios of each BAC clone are plotted on the Y axis 
according its genomic location on X axis. BACs in green represent copy number gains and in red, copy 
number losses. 
 
IDCs were significative different from mt-rich/OC at genomic level in several 
chromosomic regions: gains on chromosomes 3q29, 5q35.2, 6p21.2, 7q22.1, 8p11.1, 
9q34.11, 11q13.1, 12q13.13, 16p13.3, 17q21.2, 19q13.2 and 20q11.21, and losses on 
2p11.2, 3p12.2, 4p12, 5q21.3, 6p22.1, 7q31.31-q31.32, 10q23.1, 11p14.1, 12q24.11, 
14q13.3-q21.1, 15q15.1-q15.3, 18q21.32, 21q21.3 e Xq13.1 were more frequent in mt-
rich BC. Moreover high amplification level on chromosome 5q23.2, 6q24.2, 7q34, 
8q23.1-q23.2, 9q34.3 and 17q25.3 were associated with these tumours. 
Profiles of IDC NAS and selected mt-rich/ oncocytic (Fig. 3.19) carcinomas were 
compared using a previously validated multi-Fisher's exact test with p values adjusted for 
multiple comparison by the false discovery rate. 
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Figure 3.19: Frequency plots of amplifications in grade and ER-matched IDC-NSTs and mt-rich BCs. 
A) Frequency of gains and losses in each group. The proportion of tumours in which each clone is gained 
(green bars) or lost (red bars) is plotted (Y axis) for each BAC clone according to genomic location (X 
axis). Vertical dotted lines represent chromosome centromeres. B) Frequency of amplifications in each 
group. The proportion of tumours in which each clone is gained at high level or amplified (green bars) is 
plotted (Y axis) for each BAC clone according to genomic location (X axis). Vertical dotted lines represent 
chromosome centromeres. The bottom plots in A and B illustrate the results of the Fisher’s exact tests 
carried out on the segmented values for each clone, and those with a permutation corrected p value of less 
than 0.05 are plotted (inverse log p value Y axis) according to genomic location (X axis). P values 
associated with loss of a region are indicated as negative values. 
B 
A 
3. Oncocytic Breast Carcinomas 
129 | S p e c i a l  T y p e s  B r e a s t  C a r c i n o m a s  
 
3.3.9 Nuclear genes codifying for mitochondrial proteins 
26 out of 71 genes analysed (37%) were statistically different (p<0.05) between the 
17 mitochondrial-rich/OC tumours and IDC. Of these 26 cases, 16 presented gains and 10 
showed losses (Tab. 3.10; Figs. 3.20 – 3.21). 
Analysing only the 10 OC, 23 out of 71 genes (32%) were altered in comparison to IDC-
NSTs, 16 presented gains and 7 losses. TK2, DDX28, GOT2, SSBP1, CHCHD3, TFBP2 
resulted no more statistically significant comparing only OC with IDC. Moreover TAZ, 
MFN2, VDAC3 became statistically significant. 
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Gene Location Function 
Altered in 
Mt 
Disorders 
Gain Loss p Tumour 
TK2 (Thymidine kinase 2) 16q21 mtDNA stability 
√ (Mt DNA 
depletion 
syndrome)  
√ 0.05 Mt-rich 
SSBP1 (Single-stranded 
DNA-binding protein) 7q34 
mtDNA 
replication  √  0.05 Mt-Rich 
TOP1MT (mitochondrial 
DNA topoisomerase 1) 8q24.3 
mtDNA 
replication and 
mtRNA 
transcription 
 √  0.05* 
Mt-
Rich/OC 
DDX28 (DEAD Asp-Glu-
Ala-Asp box) 16q22.1 
mtRNA 
processing   √ 0.01 Mt-Rich 
POLMRT (mitochondrial 
DNA-directed RNA 
polymerase) 
19p13.3 mtRNA transcription  √  0.05 
Mt-
Rich/OC 
TFBP2 (Transcription 
factor B2) 1q44 
mtRNA 
transcription  √  0.05 Mt-Rich 
MTIF2 (Translation 
initiation factor IF-2) 2p16.1 
mtRNA 
translation   √ 0.05 
Mt-
Rich/OC 
PTRF 
(release factor for 
polymerase I and RNA 
transcript) 
17q21.31 mtRNA transcription  √  0.01 
Mt-
Rich/OC 
PDP2 (Pyruvate 
dehydrogenase/phosphatas
e regulatory subunit 2) 
16q22.1 mt metabolism   √ 0.05 
Mt-
Rich/OC 
PDP1 (Pyruvate 
dehydrogenase/phosphatas
e) 
8q22.1 mt metabolism  √  0.01 
Mt-
Rich/OC 
GOT2 (Aspartate 
aminotransferase 2) 16q21 mt metabolism   √ 0.05 Mt-Rich 
SPG7 (Spastic paraplegia 
protein 7) 16q24.3 mt metabolism 
√ (Hereditary 
spastic 
paraplegia)  
√ 0.05* Mt-Rich/OC 
ETHE1 19q13.31 mt metabolism  √  0.01 
Mt-
Rich/OC 
TAZ (tafazzin) Xq28 mt metabolism √ (Barth syndrome) √  0.05 OC 
SURF1(Surfeit locus 
protein 1) 9q34.2 
OXPHOS 
structure 
√ (Leigh 
syndrome) √  0.01 
Mt-
Rich/OC 
NDFUS7 (Complex I 
subunit) 19p13.3 
OXPHOS 
structure 
√ (Leigh 
syndrome) √  0.05* 
Mt-
Rich/OC 
NDFUS8 (Complex I 
subunit) 11q13.2 
OXPHOS 
structure 
√ (Leigh 
syndrome) √  0.01 
Mt-
Rich/OC 
NDUFA2 (Complex I 
accessory subunit) 5q12.1 
OXPHOS 
structure   √ 0.05* 
Mt-
Rich/OC 
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Gene Location Function 
Altered in 
Mt 
Disorders 
Gain Loss p Tumour 
NDUFA13 (Complex I 
accessory subunit, a.k.a. 
GRIM19) 
19p13.11 OXPHOS structure 
√ (PTC and 
sporadic 
oncocytic 
thyroid ca.) 
√  0.05* 
Mt-
Rich/OC 
CHCHD3 (coil-helix 
domain-containing protein 
3) 
7q32.3-q33 mt fusion  √  0.01 
Mt-
Rich/OC 
MNF2 (Transmembrane 
GTPase, Mitofusin 2) 1p36.22 mt fusion  √  0.05 OC 
IMMT (inner membrane 
mitochondrial protein, 
a.k.a. mitofilin) 
2p11.2 mt fusion   √ 0.01 
Mt-
Rich/OC 
DRP1 (dynamin related 
protein 1) 12q24.31 mt fission   √ 0.01 
Mt-
Rich/OC 
MIL1 (Bcl-2-like protein 
a.k.a.Bcl-rambo) 22q11.21 apoptosis  √  0.05 
Mt-
Rich/OC 
BAD (Bcl2-antagonist of 
cell death) 11q13.1 apoptosis  √  0.01 
Mt-
Rich/OC 
VDAC3 (voltage 
dependent anion channel 
3) 
8p11.21 apoptosis  √  0.05 OC 
TIMM44 (translocase 
inner membrane subunit 
44) 
19p13.2 
carrier (protein 
import in mt 
matrix)  
√  0.05* 
Mt-
Rich/OC 
DNC (Deoxynucleotide 
carrier) 17q25.1 
carrier (dNTP 
uptake in mt 
matrix)  
√  0.05 
Mt-
Rich/OC 
TIMM8A (translocase 
inner membrane subunit 
8A, a.k.a. DDP1) 
Xq22.1 
carrier 
(chaperone-like 
protein) 
√ (X-linke 
deafness 
dystonia 
syndrome) 
 √ 0.05^ 
Mt-
Rich/OC 
Table 3.10: Genes compared between Mt-rich/OC and IDC-NSTs. *: p<0.01 in mt-rich/OC but p<0.05 in OC. ^: p<0.05 in mt-rich 
but p<0.01 in OC. 
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Figure 3.20: Number of altered cases each analysed genes.  
 
 
Figure 3.21: Proportion of altered cases each analysed gene. The genes are grouped according their 
function. 
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3.3.10 Mitochondrial DNA sequencing 
3 cases, out of the 6 with more than 60% of mtDNA sequenced, presented an 
alteration of mtDNA (Tab 3.11). One mutation has been hypothesized to be benign, one 
silent, one could be generate damages and only one has been just reported in literature in 
oncocytic carcinoma of thyroid [34, 44]. 
 
Sample Nucleotidic Change Gene 
Aminoacid 
Change 
Effect 
(PolyPhen or 
Mitomap) 
Mit11 T10237C het ND3 60 Thr>Ile Possibly damaging (PSIC 2,372) 
Mit15 3571insC ND1 - Complex I damages^ 
Mit19 C12964 homo ND5 210 Leu>Ile Benign 
Mit19 T729C homo 12S - - 
Table 3.11: Mt-DNA Alterations mt-DNA observed in OC samples. T: Thymine; C: Cytosine; 
het: heterozygosis; homo: homozygosis; ins: insertion; Thr: Threonine; Ile: Isoleucine; Leu: Leucine. 
Effect of mutation has been hypothesized by a prediction tool (PolyPhen). ^[34, 44] 
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In table 3.12 molecular results are summarized: number of altered genes codifying 
for mitochondrial protein (with gain or losses); OC/ mt-rich cluster group according to 
“smoothed” or “thresholded” analysis; alterations of mitochondrial DNA. 
 
 Mt ICH Tumour Smoot. Thres. Gains Losses mtDNA alt. 
Mit3 2+ (70%) Mt-Rich IN IN 13 6 - 
Mit4 3+ (90%) OC OUT OUT 5 4 NO 
Mit5 2+ (90%) Mt-Rich OUT OUT 3 5 NO 
Mit6 2+ (70%) Mt-Rich OUT OUT 10 5 - 
Mit7 3+ (90%) OC IN OUT 11 2 NO 
Mit8 3+ (90%) OC IN IN 16 5 - 
Mit9 3+ (90%) OC IN IN 17 1 - 
Mit10 2+ (70%) Mt-Rich IN IN 9 9 - 
Mit11 2+ (70%) Mt-Rich IN IN 11 2 T60I 
Mit12 3+ (90%) OC IN IN 11 5 - 
Mit13 3+ (80%) OC IN OUT 4 6 - 
Mit14 2+ (80%) Mt-Rich IN IN 5 7 - 
Mit15 3+ (80%) OC IN IN 3 8 3571insC 
Mit16 3+ (90%) OC OUT IN 6 2 - 
Mit17 Neg Ctrl OUT OUT 2 0 - 
Mit18 3+ (90%) OC OUT IN 7 9 - 
Mit19 3+ (90%) OC IN IN 4 5 L210I 
Mit20 2+ (70%) Mt-Rich OUT OUT 5 7 - 
Table 3.12: Molecular features of 18 samples analysed by aCGH. Mt-IHC: positivity for anti-mitochondria 
antibody; Ctrl: control; Smoot.: smoothed; Thres.: thresholded; IN: included in cluster; OUT: out of cluster; 
Gains/Losses: number of nuclear genes, codifying for mitochondrial protein, with gains or losses; mt-DNA alt: 
mtDNA alterations. 
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3.4 DISCUSSION AND CONCLUSIONS 
 
Oncocytic tumours have been described in several organs, even if with different 
frequencies. The percentage of neoplastic cells need for classifying a tumour as oncocytic 
is different according to organ. For example, in thyroid the proportion is 75% [3, 4], 
while in kidney the tumour should be entirely composed by ossifilic cells [5]. Even if this 
tumours could arise in any organs, endocrine system and some parenchymatous organs 
seem to be particularly prone to develop this type of carcinoma. Thyroid is the main site 
of onset, then kidney, salivary and parotid glands, while gastrointestinal and respiratory 
tract and skin are rarely affected [45]. With regard to breast, till now only 4 cases have 
been reported in literature [13, 14]. 
In this study we have analysed 33 cases of oncocytic invasive breast carcinoma of the 
breast, selected according to morphological (cells with wide and eosinophilic cytoplasm) 
and immunohistochemical criteria (at least 70% of neoplastic cells strongly positive for 
anti-mitochondria antibody). For performing a semiquantitative analysis of mitochondria 
inside neoplastic cells, we have optimized a safe and consistent immunohistochemistry 
reaction. 
Oncocytic carcinomas have reported a frequency of 19.8%. Moreover we have 
observed another group of “mitochondria-rich” breast tumours: these carcinoma could be 
morphologically not distinguishable from oncocytic carcinoma and are differentiated only 
according to immunohistochemistry. 
The 4 cases reported in literature were all well or moderately differentiated (GI or GII) 
and, in one case, was an in situ carcinoma. In this study we have considered infiltrating 
type and we have observed a prevalence of GIII carcinoma, characterized by solid nest 
growth pattern and infiltrative margins. We found cytological characteristic reported 
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previously in literature (monomorphic nuclei, prominent nucleoli and rare mitosis) only in 
well differentiated form (GI and some GII). Moreover our cases could show other 
features as nuclei with faint to strong pleomorphism, cells with at least two nuclei and 
inconspicuous nucleoli. Cytoplasm was characteristically wide and eosinophilic. 
Immunohistochemically, most part of the cases showed a luminal profile, with CK7 
and EMA expression and positivity for hormonal receptor, especially oestrogenic. In one 
case we observed a case with basal features, CK14 positive and NEU and hormonal 
receptors negative. Interestingly, could coexist apocrine, neuroendocrine and/or mucoid 
differentiation. 
Interestingly, CK7 resulted negative or focal in 8 cases and this could be a diagnostic 
trouble, in the event of metastatic localization of these carcinomas. 
The evidence that mitochondrial accumulation is a slow phenomenon and that cellular 
culture of oncocytic tumours tend to loss this phenotype after “n” replication, has lead to 
hypothesize that oncocytic neoplasia are benign or with low grade of malignancy [11]. 
This is true for oncocytoma of kidney, parathyroid, pituitary gland, and for fibrolamellar 
epatoma, but in other site the prognosis of oncocytic carcinoma is overlapping to those of 
non oncocytic part, as in gastroenteric tract, or could be worst, as in thyroid, salivary 
glands and meningioma. 
With regard to prognosis, we have not found statistically significant differences 
between oncocytic and non-oncocytic carcinomas. However, we have observed a 
tendency to worst prognosis of OC, and this trend is statistically significant comparing 
OC/mt-rich grade II with not enriched in mitochondria grade II. 
Mitochondria are cytoplasmatic organelles involved in several processes of cellular 
homeostasis, as ATP production by respiratory chain and apoptosis by releasing 
cytocrome c in intermembrane space [46]. In 1956, Otto Warburg demonstrated as human 
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tumours presented an increase in glycolysis rate with reduction of OXPHOS chain 
activity even in presence of oxygen, suggesting that defects in this mechanism could be at 
the base of many type of neoplasia [18]. This dependence of tumoural cells on glycolysis 
for ATP production, is considered a typical aspect of malignant transformation, together 
with 6 principle alteration of cellular physiology described by Hanahan e Weinberg 
(independence on promoting and inhibiting growth factors, limitless replication, induction 
of angiogenesis, invasive and metastatic skill and apoptosis evasion) [17]. In last year’s, 
the discover of mitochondrial DNA mutation and of nuclear genes codifying for 
mitochondrial protein in many sporadic or familiar tumour with or without oncocytic 
features, has supplied genetic bases of mitochondrial dysfunction observed in 
tumourigenesis. From a molecular point of view, the most studied oncocytic tumours are 
the thyroid one, in which has been observed a wide deletion in mt-DNA, called “common 
deletion”. This alteration concerns 7 genes involved in respiratory chain and it is a 
characteristic defects of oncocytic neoplasia of thyroid [46]. 
In our study, molecular results obtained by aCGH show that OC and mt-rich harbour 
characteristic chromosomic aberration in comparison to IDC NOS. Unsupervised 
hierarchical analysis revealed that OC and mt-rich tend to form a distinct cluster as 
opposed to IDC NOS. Although mitochondria have own DNA, producing 13 out of 87 
protein arranging enzymatic complex involved in oxidative phosphorilation, most part of 
the protein are codified by nuclear genes. Analyzing these genes, we have observed that, 
out of 71 genes under study, 26 showed differences (gains and losses) statistically 
significant between OC/mt-rich and IDC NOS groups. Most part of these genetic 
alterations involves enzyme or proteins are associated with mitochondrial genome (for 
example operate in replication, transcription, traduction or stability). 
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With regard to sequencing of mitochondrial genome, we have not observed 
significant alterations, even if we know that the number is not sufficient to hypothesize 
some theory. 
These molecular results, other than confirming that OC/mt-rich carcinomas represent 
a particular and independent entity in breast carcinoma overview, suggest that 
mitochondria aggregation is not only a simple morphologic correlation with oncocytic 
phenotype but could play a functional role. 
In conclusion: 
• Oncocytic breast carcinoma is a morphologic entity with distinctive ultrastructural 
and histological features. 
• Immunohistochemically, it is characterized by a luminal profile and could be 
associated with an apocrine, neuroendocrine and/or mucoid differentiation. 
• In our study it has a frequency of 19.8% out of invasive breast carcinomas. 
• It is not characterized by specific grade or stage 
• It has not distinctive clinical features and we have not observed significant 
differences in comparison invasive breast carcinoma with regard to prognosis. 
• At molecular level, OC/mt-rich carcinoma clusterizes independently from IDC 
NOS and show a specific constellation of genetic aberration. 
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